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Summary 
This thesis entitled ‘Squaramide-Naphthalimide Conjugates as Potential Self-Assembled 
Materials and as DNA Binders’ is divided in 7 chapters. Chapter 1 presents an introduction to 
DNA, its function and structure. Various DNA binders were introduced in this section, 
specifically currently studied naphthalimides as DNA intercalators, with potential as possible 
treatments for various types of cancers. The H-bonding ability of squaramide and its potential 
as a DNA binder to the negatively charged sugar phosphate backbone was discussed. Bis-
intercalators were also described in detail and their strong DNA bis-intercalating ability was 
also discussed. The proposed target bis-intercalators were introduced, with multiple modes of 
binding to DNA, where the naphthalimide moieties would bis-intercalate into DNA, while the 
squaramide would bind to the negatively charged sugar phosphate backbone of DNA. 
 
In Chapter 2, the design and synthesis of novel compounds are discussed. The syntheses of the 
desired compounds, the challenges encountered during synthesis and the change in the design 
of the desired compounds was also described. Each compound was characterised with room 
temperature NMR and it was concluded that after VT-NMR studies were performed, which 
clearly indicated self-assembly properties of these novel compounds. 
 
Chapter 3 describes the self-assembly properties of the novel squaramide containing bis-
naphthalimides, which will involve various techniques including VT-NMR, UV absorbance 
time studies, extinction coefficient studies and Scanning Electron Microscopy. 
 
Chapter 4 discusses the possible DNA binding ability of the novel synthesised compounds 
using UV-Vis absorbance, fluorescence and Ethidium Bromide Assays. 
 
Chapter 5 gives an overall conclusion of the entire work carried out in this research and also 
provides a perspective with the ideas for future work. 
 
Chapter 6 contains the general experimental procedures including the synthesis and detailed 
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Chapter 1  DNA and DNA targeting synthetic compounds 
1.1  Introduction to DNA 
Deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic instructions for the 
development and function of all living things.1 DNA is mostly located in the cell nucleus 
(nuclear DNA) while being less abundant in the mitochondria of a cell (mitochondrial DNA).2 
DNA is a long polymer made up of simple units called nucleotides, which are held together by 
a backbone of sugars and phosphate groups (Figure 1.1).3 As originally hypothesised by 
Watson and Crick, semiconservative DNA replication is carried out by all living organisms.1 
The three molecular fragments that make up the nucleotide are: sugar, heterocycle and 
phosphate, while the cyclic furanoside deoxyribose sugar is connected with one of the four 
heterocyclic bases by an 8-glycosyl linkage.1 The sugar-phosphate backbone runs at the curve 
of the helix in an antiparallel orientation. The Base-pairs (A-T and G-C) along the centre of the 






Figure 1.1:  Proposed schematic structure of the DNA double helix by Watson and Crick in 1953.1 
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1.2  Structure of DNA 
DNA is wound into a right-handed double helix in order to be protected from the outside 
environment (Figure 1.2).5 The two grooves in the helix (major and minor) are defined by the 
right-handed twist of the DNA backbone (in B-form DNA) which are lined by the sugar 
phosphate backbone.6 The negatively charged sugar phosphate backbone carries four types of 
molecules called bases which are: Adenine, Thymine, Guanine and Cytosine and it is the 
sequence of these four bases that encodes genetic information.7 It is also important to view the 
individual components of DNA to truly understand the structure of DNA B-form as well as the 
various structural variations in the DNA right-handed double helix. There are a number of 
possible variations in the helical structure of DNA due to numerous possibilities in the 
structures of the sugars and the bases and to the structural relationship of the bases to the 
sugars.8 It is known that DNA (right-handed double helix) is formed by two individual strands 
which are aligned in an anti-parallel fashion, which means that one strand is oriented from the 
5’ end to 3’ end, while the other strand is oriented from the 3’ end to the 5’ end, where the 
adjacent nucleotides are linked due to the formation of phosphodiester bonds, caused by the 
phosphate group attachment to the 5’ end of one nucleotide and the hydroxyl group at the 3’ 
end of another nucleotide.9 This linkage enables the structural rigidity of DNA due to the sugar-
phosphate backbone. The 3-dimensional double helix structure of DNA correctly elucidated 
by James Watson and Francis Crick. Complementary bases are held together as a pair by 
hydrogen bonds.10  
 
Figure 1.2:  The double-helical structure of DNA.5 
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1.3  DNA base pairs 
DNA base pairing is the aspect where guanine is always bound to cytosine and adenine is 
always bound to thymine via hydrogen bonding (Figure 1.3). The bond between guanine-
cytosine share three hydrogen bonds compared to the adenine-thymine bond which always 
share two hydrogen bonds.3 Complimentary purine-pyrimidine base pairing increases the 
stability of the double helix, as it keeps a constant distance between the two polynucleotide 
strands.11 The stability of the double helix is enhanced by the weak and numerous Hydrogen-
bonds between the complementary bases. The processes of transcription and DNA replication 
are made possible by enzymes which are responsible for breaking the Hydrogen-bonds. 
Complementary base pairing is crucial as it is essential in forming the helical structure of DNA, 
due to the base pairs having the most stable position.12 It is also important in replication as it 
allows semiconservative replication.13  
 
Figure 1.3:  DNA structure including the complimentary base pairs.3 
(A) DNA double helix, containing the nitrogenous bases in the middle, while the negatively charged 
sugar phosphate backbone is positioned on the outside. 
(B) Adenine-Thymine and a Guanine-Cytosine base pairs, where the arrow indicates C1′ of the 
deoxyribose. The atoms on the lower edge of the base pair face into the minor groove, while the atoms 
on the upper edge face into the major groove. The C1’ of the deoxyribose has been highlighted to be 
positioned in the same locations of all base pairs. The dotted line also illustrates the hydrogen bonds 
between the base pairs.14 










1.4  Function of DNA 
The major function of DNA is to encode the sequence of amino acid residues in proteins, using 
the genetic code.15 Importantly, the covalently bonded sugar-phosphate backbone is 
responsible for storing the base sequence of genetic information of the cells, while also 
allowing the shortening of DNA during the process of cell division.11 The genetic function of 
DNA can be explained as an alliance of two properties which include: a strand which contains 
the necessary information which encodes the sequences of RNA molecules and sequences of 
proteins as well as a polymer which enables the packaging, replication as well as the 
accessibility of the information, as it exists as a double helical string.16 Although DNA does 
indeed play a crucial role as it stores genetic information, it also plays a role of adopting a large 
variation of possible conformations, which include: cruciforms, quadrupex DNA, 
intramolecular triplexes and left handed z-DNA to name a few.8 Another key function of DNA 
in a cell nucleus is that it also acts as a store of energy in order to enable the transport of DNA 
and RNA polymerases. It is the double-helical structure of DNA that does indeed enable this 
process as it can exist in the coiled or supercoiled forms.17 The stability of the double helix is 
achieved due to the stacking of the bases and it is known that there are 10-10.5 base pairs per 
turn of the double helix.18 
 
1.5   Negatively charged sugar phosphate backbone 
DNA backbone is a negatively charged repetitive chain of interconnected sugar and phosphate 
groups as it is situated on the outside of the double helix (Figure 1.3).8 Interconnected sugar 
and phosphate groups are responsible for making up a repetitive chain of a DNA backbone.19 
The structural frame work of DNA nucleic acids are formed by the sugar-phosphate backbone 
and this backbone is responsible for defining the directionality of the molecule.20 DNA-protein 
interactions are facilitated by the dynamic properties of the DNA backbone.21 The backbone 
utilises the control over the base stacking geometries by two crucial mechanisms which are:  
1) The sugar-phosphate backbone is well known to have a limited length and thus, it limits the 
conformational space which is accessed by the bases. 
2)  The neighboring base pairs in a sequence are held by the backbone in order to embed the 
structures of the same dinucleotide in different sequence contexts in a series of tetranucleotides, 
which may enable the possibility of having variable differences.22 The phosphate backbone 
provides a means for DNA recognition through electrostatic or H-bond interactions amongst 
others. 
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The bases: Adenine, Thymine, Guanine & Cytosine are shown to bind to the negatively charged 
phosphate backbone. The anti-parallel nature of the two backbones are also displayed, where 
one strand runs from the 5’ end to the 3’ end and the other strand runs from the 3’ end to the 
5’ end.23 
1.6  DNA binding and recognition 
A DNA-binding domain (DBD) is a protein that is responsible for recognising single or double 
stranded DNA as it is known to contain at least one structural motif.24 A DBD has a general 
affinity to DNA or it can distinguish a recognition sequence of a specific DNA sequence.25 An 
interesting non protein alternative which regulates transcription is the use of synthetic small 
molecules which are able to bind DNA.26 Controlling gene expression has successfully proven 
to be a means of therapeutic development.27 Both natural and synthetic small molecules that 
strongly bind in the groves have been designed to inhibit DNA-protein interactions, since these 
interactions engage contacts in minor and major grooves of DNA.28 Molecules that fit between 
DNA base pairs can also directly or allosterically disrupt DNA-protein interactions. Therefore, 
low molecular weight DNA binders are used in drug discovery projects as they are able to act 
as inhibitors of gene expression.28 Small molecule studies, including both current and potential 
drugs, have shown that they can be classified as intercalators, multi-mode binders, groove 
binders, multi-mode and single chain ligands.29-32 
 
1.7  Binding interactions of synthetic compounds with DNA 
The main binding interactions of [small molecules/synthetic compounds/potential drugs etc] 
can include electrostatic, allosteric, hydrophobic, hydrogen bonding and/or Van der Waals 
interactions.29, 30 Previous studies have proven that small molecules with an overall positive 
charge are very likely to bind to DNA grooves in the initial and the final state (Figure 1.4).33, 
34 
Figure 1.4:  Three types of DNA binders including; A=External electrostatic binder,  
B=Groove binder, C=Intercalator. The drug is represented by the pink bar in each type of binders.29, 33 
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1.7.1 Electrostatic interactions 
Ions or small molecules that bind externally with DNA are generally not specific to the 
sequence and position of the nucleotides. Their distribution is mainly determined by the 
electrostatic interaction with negatively charged phosphate groups in the DNA backbone.35 Li+, 
Na+ and K+ are examples of ions that bind in this non-specific way. However, ions such as Ag+ 
and Hg2+ are examples of ions that specifically bind to the nucleobase.36 Cationic polyamines 
are examples of small molecules that have been examined in a number of studies to externally 
bind to DNA.37 External binding is electrostatic in nature and generally is characterised by 
binding kinetics approaching the diffusion limit of Ka = 10
7-108 M-1s-1 as it does not require 
significant DNA structure changes.35 A number of metal ions bind to DNA via an electrostatic 
bond, also known as an external non-specific external association.38 Synthetic compounds are 
able to interact with the electron donating parts of the DNA bases or they can covalently or 
non-covalently bind to the negatively charged phosphate DNA backbone.39 The hydrophilic-
hydrophobic structure of the molecule, the charge on the compounds and the overall size of the 
ions determine the intensity of these types of interactions. The DNA double helix structure 
results in damage following the interaction between the compound and DNA phosphate 
backbone.39 Reversible intermolecular interactions including electrostatic bonds result from 
the interaction between the cations and the negatively charged phosphate on the outer surface 
of the DNA helix.40  
 
There are various different types of molecules that can interact with this outer edge, generally 
through non-specific electrostatic interactions.41 Metal ions such as Na+ and Mg2+ are bound 
in an aqueous solution, but spermine 2 and spermidine 3 are examples polyamines of externally 
DNA linked differentially methylated genes.42 Due to the unspecific nature of the binding, the 
mechanisms of action are unknown. However, polyamines are likely to neutralize negative 
charges on the DNA phosphate backbone, thereby promoting DNA packaging, which is an 
essential process for cell proliferation.43 Polypyridyl metal-ruthenium(II) complexes have been 
studied and examined in great detail in the past 25 years due to their excellent photophysical 
properties and their high affinity for binding to DNA.44, 45 These complexes strongly bind to 
DNA via electrostatic interactions to the phosphate backbone due to their positive charge.46, 47 
These Ru2+ complexes can also be varied with ligands which can also intercalate with DNA.48 
Mihailovic et al. had synthesized the Ru2+ complex, 1 which comprised of bipyridine ligands 
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for enhanced electrostatic interaction to the DNA, where Ru2+ was bound to the backbone of 
the negatively charged phosphate DNA (Figure 1.5).49 
 
Figure 1.5:  Synthesised electrostatically DNA binding Ru2+ metal complex [Ru(bpy)3]2+, 1 by 
Mihailovic et. al.49 
 
One of the compounds synthesised by the group showed concentration-dependent cytotoxicity 
in HeLa cells and mesothelioma cells.49 The cytotoxicity of the compound against the cell lines 
was found to be between 8.8 and 43 µM, while also having possible uses as a novel PDT 
agent.49 
 
1.7.2 Allosteric interactions  
Allosteric interactions take place when the binding of a ligand to its site on a receptor can alter 
the binding of another ligand to a topographically different site on the same receptor and vice 
versa.50 Allosteric mechanisms have many advantages as these interactions make it possible to 
regulate a specific reaction step by the products of other phases of the reaction pathway or 
altogether from other reaction pathways.51 Allosteric interactions also allow specific regulation 
of an enzyme. For example, it is difficult to directly block a specific ATP binding site by 
forcing the regulator to compete for the target enzyme at high ATP concentrations and not to 
bind to multiple ATP binding sites that are linked to other proteins.51 It is well known that 
biological systems utilise allosteric regulation, as Monod predicted almost 40 years ago.51 
Recent studies have shown that the development of new classes of allosteric drugs can be 






Figure 1.6:  Chemical structures of synthesised compounds that bind to DNA with allosteric 
interactions. 
 
The development of ligands that solely bind to the receptor's orthosteric hormone binding site 
is the result of numerous attempts to discover various drugs at the β2 adrenergic receptor 
(β2AR).53 Nonetheless, there is a vast potential for designing specialised drugs with fewer side 
effects than orthosteric ligands when targeting the generally unexplored unique allosteric 
sites.53 Remarkable isoenzyme selectivity can be demonstrated due to large transfer in the 
binding site caused by the allosteric binding compounds.52 Compound 2 hinders p38α MAP 
kinase in the nanomolar range with stronger selectivity than the kinome, due to its activated 
adaptive binding mode demonstrated by X-ray crystallography.54 Phosphoinositide 3-kinase α 
(PI3Kα) inhibitor 3 is a kinase inhibitor with a different binding mode, as it binds to the ATP 
binding site.55 Compound 4, is known to be selective for closely related members of the 
Bruton’s tyrosin kinase and Cyclin G-associated kinase families.52 The selection for a 
completely different class of encoded compounds, namely peptide macrocycles, resulted in 
compound 5, the Src allosteric kinase inhibitor.56, 57 Compound 6, demonstrated the ability of 
the inhibitor to block RIP1 kinase hydrolysing ATP to ADP with a cellular potency. It targets 
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type III allosteric site at the back of the ATP binding, where the benzyltriazole portion is bound 
in the allosteric lipophilic pocket and the benzoxazepinone heterocycle binding in space that 
the γ-phosphates of ATP would be present in.52 Nanomolar potency of 7 has been demonstrated 
in its inhibition of the poly (ADP-ribose) polymerase Tankyrase 1.52 Inhibitor 8 utilises 
selective inhibition of the protein arginine deiminase 4 (PAD4) isoenzymes via Induced Fit-
Type Mechanism, where the binding of 8 to PAD4 causes a change in the shape of the enzyme 
in order to inhibit its activity.58 The Wip1 inhibitor 9 hinders the phosphatase in a non-
competitive mechanism of action as it targets a binding site outside the catalytic centre.52 
Insulin Degrading Enzyme (IDE) inhibitor 10 is a macrocycle known for its binding to an 
allosteric binding site, which eliminates the need for a metal ion binding group leading to off-
target activity.52 IDE inhibition is a possible treatment option for diabetes due to elucidating 
























1.7.3 Hydrophobic interactions 
Distamycin, 12 is an antibiotic used to treat fungal infections (Figure 1.7).59, 60 Predominantly, 
derivatives of distamycin are well known to have anti-tumour activity.61, 62 Hydrophobic 
interactions and hydrogen bonds are the result of Distamycin binding with these DNA A-T rich 
regions in the minor groove (Figure 1.8).63 Distamycin is attracted to the negatively charged 
sugar phosphate backbone of DNA due to its basic terminal amidine group.64 Distamycin is A-
T selective as it is restricted from binding to the minor groove of the G-C base pairs due to 
steric hindrance.64 
 
Figure 1.7:  Chemical structure of Distamycin A, a polyamide antibiotic. 
 
 
Figure 1.8: DNA binding of Distamycin: View of the DNA duplex strand (purple) and distamycin 




Actinomycins, 13 are a class of antibiotics known for their inhibition of both RNA and DNA 
syntheses processes by creating a barrier preventing chain elongation, as actinomycins are used 
in the treatment of Wilms tumour, trophoblastic neoplasm, Ewing’s sarcoma and various types 
of ovarian cancers (Figure 1.9).65, 66 
 
 
Figure 1.9:  Chemical structure of Actinomycin-D, a polypeptide antibiotic. 
 
Actinomycins, in contrast to distamycin, require the 2-amino group of guanine for binding in 
the G-C base pairs.67 The side chains of the pentapeptides of actinomycins are known for their 
ability to form hydrogen bonds and hydrophobic interactions in the minor groove of DNA, 
while the phenoxazone ring intercalates in between the base pairs (Figure 1.10).63, 64 A very 
stable complex is formed as a result of both interactions of actinomycin with DNA (minor-




Figure 1.10:  DNA binding of Actinomycin: View of the DNA duplex strand (purple) and 
actinomycin D (orange), where the pentapeptides of actinomycin bind to the minor groove, while the 
phenoxazone ring intercalates in between DNA base pairs. 
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1.7.4 Hydrogen bonding interactions 
Magnesium ions are known to be essential in both the structure and function of nucleic acids.68 
There is very little known about the interactions of RNA helical regions with magnesium ions, 
although the process of RNA tertiary folding frequently uses magnesium ions when binding to 
clustered phosphates of RNA.68 [Mg(H2O)6]
2+ is known to have two binding modes to both A-
DNA and RNA (Figure 1.11).68 
 
Figure 1.11:  (A) [Mg(H2O)6]
2+ and its two binding modes to RNA-DNA duplex of 
r(GCG)d(TATACGC), where; three Mg2+ ions Mg I, Mg II and Mg III labelled (I,II and III) bind 
directly via hydrogen bonding to the O6 and N7 sites of guanine bases (represented by red and blue 
spheres). 
(B) Major groove of DNA being almost entirely filled by the three [Mg(H2O)6]
2+ ions, where the first 
shell bound aqua regions are located (red). 
 
Three Mg2+ ions bind directly via hydrogen bonding to the O6 and N7 sites of guanine bases.69 
[Mg(H2O)6]
2+ ions are also very well known to bind to the A-DNA phosphates at the outer part 
of the A-DNA major groove via electrostatic interactions, proven by their presence at the most 
negative electrostatic potential sections.68 The [Mg(H2O)6]
2+ ion can access the edges of the 
A-DNA base pairs, although it is much larger (approximately 8Å in diameter) than the outer 
part of the major groove average width.68 
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1.7.5 Major/Minor-Groove binders 
DAPI, 14 (Figure 1.12) selectively binds into the minor groove of DNA with a preference for 
the adenine-thymine regions, resulting in a decrease of the bending rigidity of DNA.70-73 
Berenil, 15 binds to the minor groove of DNA also via attachment to the minor groove of AT-
rich domains of DNA helices.74 Pentadimine, 16 has been widely studied in the treatment for 
human protozoan infections, where the mechanism of action also involves selective binding to 
the AT-rich regions of DNA.75-78 Hoechst 33258, 17 is used as a fluorescent dye, as it binds to 
DNA by forming extensive van der Waals forces and via binding to the minor groove of DNA 
phosphate backbone (Figure 1.13).79, 80 
 












Figure 1.13:  Hoechst 33258 bound to DNA [5’-d(CGCGAATTCGCG)2-3’] via hydrogen bonds 
highlighted by the black dashed lines. 
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Distamycin-DNA and netropsin-DNA interactions rely heavily on H-bonds, although H-bonds 
do not make an important contribution in recognising Hoechst 33258 with DNA (Figure 
1.14).80 It has been proven that netropsin, 18 forms eight hydrogen bonds when bound to 



























Figure 1.14:  Binding of netropsin to DNA [5’-d(C5-BrCCCCIIIII)2-3’] via van der Waals forces (A) 
and its binding to DNA via hydrogen bonding highlighted by the black dashed lines (B). 
Binding of distamycin to DNA [5’-d(GTATATAC)2-3’] via van der Waals forces (C) and its binding 
to DNA via hydrogen bonding highlighted by the black dashed lines (D). 
 
In DNA sections, the groove binders have been proven to increase the transitional force of 
excessive DNA stretching, as both Methyl Green and distamycin, both major and minor groove 
binders, increased the transition strength, indicating a stabilisation of the DNA double helix.82 
It had also been proven that the DNA melting cooperativity had decreased due to the presence 
of major groove binders, as the over stretching of a transition force range had been broadened.83 
Intercalation is the final state of the binding modes which is caused by groove binding as it is 
often an intermediate state.33 
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Berenil is an example of a drug that intercalates DNA at higher concentrations but binds in the 
minor groove at low concentrations (Figure 1.15).30, 84 Some small molecules can thread 
between the DNA base pairs before the process of intercalation takes place, as they have higher 
orders of complexity of DNA binding intercalation.85, 86 Although binding to single-stranded 
DNA (ssDNA) is the least common type of binding, as reported for DNA glyoxal binding,87, 88 












Figure 1.15:  Hydrogen bond interaction between DNA and Berenil. 
 
The molecular recognition of B-DNA can be done in five different ways: major groove 
recognition; minor groove recognition; sugar-phosphate backbone binding; intercalation 
between the base pairs; covalent binding or metal-coordination to the bases.89 Developing ways 
of inhibition of protein-DNA interactions are vital in terms major groove specific ligand-DNA 
interactions (Figure 1.16).90, 91  
 
Figure 1.16:  (A) DNA double helix representing major groove of A-DNA (PDB ID: 2ANA), (B) 
DNA double helix representing major groove of B-DNA (PDB ID: 1D98), (C) base pair hydrogen bond 
donor/acceptor in the major and minor groove of A-DNA and (D) base pair hydrogen bond 
donor/acceptor in the major and minor groove of B-DNA. 
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It has been proven that natural molecules such as: ditercalinium, aflatoxin, neocarzinostatin, 
pluramycin, azinomycin and leinamycin have potential major-groove binding characteristics.92 
Nonetheless, these compounds mainly interact with DNA through the process of 
intercalation.91, 93 According to recent studies, aminoglycosides have proven to be promising 
probes for DNA major groove binders.91 Nonetheless, major groove binding is an emerging 
area of interest in DNA interaction, as proteins and many biological macromolecules mostly 
bind to DNA via major groove through a series of hydrogen bonds.91 
 
Pluramycin, 20 is a widely used antibiotic in the treatment of various cancers due to their strong 
biological activity (Figure 1.17).91, 94 Altromycin B, 21 and Hedamycin, 22 are the most active 
antitumor antibiotics of the pluramycin family (Figure 1.18).95, 96  
 
 
Figure 1.17:  Chemical structures of pluramycin A, 20, altromycin B, 21 and hedamycin, 22. 
 
 
The reactivity of pluramycins is intensified by TBP binding to the human myoglobin TATA 
sequences on DNA.97 Although pluramycins intercalate between the DNA base pairs, the N7 
position of guanine of the purine bases in the major groove become alkylated in the presence 
of the adjacent epoxide rings of pluramycins, which facilitate covalent bonding (Figure 1.18).91, 
98 The glycosidic substituents regulate the selectivity of sequences, due to the presence of 
oligonucleotide substrates with altromycin B and hedamycin alkylated complexes.99, 100 The 
DNA melting temperature is increased by 20°C due to the presence of hedamycin, which 




Figure 1.18:  Chemical structure of bis-altromycin B with the processes of alkylation at N7 
(turquoise), saccharide binding in major and minor grooves of the double helix (yellow) and 




1.7.6 Covalent interactions 
The covalent bond in DNA is irreversible and always leads to cell death due to DNA process 
inhibition.102 Cis-diamminedichloroplatinum (cis-platin), 23 a very well-known anticancer 
covalent DNA binder (Figure 1.19).102 Cis-Platin has been widely used for over 40 years for 
the treatment of testicular, ovarian, neck and head cancers.103 Cis-platin uses its chloro groups 
to form an inter/intrastrand cross-link with the nitrogens on the bases of DNA.102 
 
Figure 1.19:  Covalent binding of cis-platin with DNA. 
 
Various alkylating agents have been developed in the past twenty years, due their strong 
anticancer activity.104 DNA miscoding is the result of alkylating agents suppressing the process 
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of DNA base pairing, due to binding with the N-3 of adenine and particularly with the N-7 of 
guanine nitrogen bases of DNA.105 DNA fragmentation is the result of repair enzymes 
replacing the alkylated bases of DNA which are a result of cisplatin induced DNA damage.106 
Cross-bridge formation is an additional DNA damage mechanism in which the DNA is 
prevented from being separated for either transcription or synthesis due to the formation of 
bonds between the atoms in the DNA.104 Mutations result from the process of mispairing of 
nucleotides of DNA, where a particular nucleotide is replaced by another due to errors in DNA 
replication, caused by alkylating agents. This is known to be the third mechanism of action of 
alkylating agents.107 
 
Monofunctional Pt-DNA adduct is formed as a result of cisplatin initially forming a single 
covalent bond with DNA.108 1,2-Pt-d (GpG) intrastrand crosslink is the most abundant cisplatin 
formed species, which makes up approximately 60% to 65% of all adducts formed by 
cisplatin.109 Both 1,3-Pt-d(GpXpG) and 1,2-Pt-d(ApG) are much less abundant cisplatin 
formed species, which together make up approximately 30% of all adducts formed by cisplatin 
(Figure 1.20).110, 111  
Further DNA strand breaks are caused by transcription inhibition, DNA unwinding, replication 
inhibition and DNA unwinding caused by the different crosslinks and adducts of cisplatin due 
to the Pt-d(GG) interstrand crosslinks.112 Carboplatin, 24 and Oxaliplatin, 25 are the less toxic 
derivatives of cisplatin developed in recent times which also highlight the success of cisplatin 
as a strong anticancer agent (Figure 1.21).113, 114 
 
 




Figure 1.21:  Chemical structures of cisplatin, carboplatin and oxaliplatin.  
 
1.7.7 Metal-coordination to the bases 
Numerous recently developed metal complexes have become effective chemotherapeutic drugs 
and diagnostic agents.115 Using a metal ion to substitute the hydrogen atom in the hydrogen 
bonded base pairs was the base idea which had led to the development of metal-mediated base 
pairs due to both accepting lone pairs on the heteroatoms.116 Lee et al. discovered that divalent 
Zn2+ ions stabilise DNA duplexes,117 where at high pH, they release hydrogen atoms that are 
bound to the base pairs and the metal ions are responsible for binding to the nucleobases.118 
The development of these metal complexes with stronger anticancer activity and minimal 
toxicity compared to the standard platinum complexes is one of the main challenges in the 
therapeutic field.119 DNA synthesis, energy metabolism and respiration are all functions of 
numerous enzymes involving the copper metal.119 This creates the possibility of using other 
alternative metal complexes exhibiting copper-based antineoplastic activity.120, 121 Free 
radicals are generated due to hydrogen peroxide and molecular oxygen being prone to reacting 
with copper involving redox reactions in these strongly biologically active copper 
compounds.122 DNA and RNA are directly cleaved due to the displacement of other metal ions 
as a result of the ability of copper to produce reactive oxygen species (ROS) and this explains 
the strong biological activity of copper.123 Casiopeinas, 26 are a family of compounds 
synthesised on the basis of designing copper(II) coordination complexes which are known to 
trigger DNA cleavage.119, 124, 125 [Cu(N-N)(O-O)]NO3 or [Cu(N-N)(N-O)]NO3  are the general 
formulas of these complexes , where N-N represents a 1,10-phenanthroline or a substituted 
bipyridine; N-O represents a peptide or an a-amino acid, while O-O indicates salicylaldehyde 







Figure 1.22: (A) Cas ([Cu(2,2’-bipyridine)(acetylacetonate)(H2O)]+). 
          (B) CCDC 737505 X-ray structure. 
 
This family of compounds have been classified as genotoxic,126 cytotoxic in vivo and in vitro125 
with possessing strong antineoplastic activity.127 Dose-dependent cell death is achieved by 
apoptosis due to the inhibition of cell proliferation by the Casiopeinas compounds,128 resulting 









Figure 1.23:  Chemical structure of PBD-BIMZ (A), Schematic displaying PBD-BIMZ with bound 
to DNA duplex (B), Chemical structure of PBD-naphthalimide (C), (D) Schematic displaying PBD-
naphthalimide bound to DNA duplex. The synthesised molecule is represented by the orange complex, 
nitrogen atoms are represented by blue atoms, oxygen atoms are represented by the red atoms and the 
purple structure represents the negatively charged sugar phosphate backbone. 
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1.7.8 Interactions by intercalation 
Limited intercalation in between two base pairs of particular side-chains of proteins is the result 
of the critical protein-DNA recognition processes.131 The β-sheet domain of the TBP protein 
binds to the minor groove of the DNA TATA-box in addition to the side chains of 
Phenylalanine residues binding in between the base pairs via the process of intercalation.132 
The hinge region is particularly prone to the intercalation of the side chains of Leucine residue 
between the DNA binding domain (DBD) and the C-terminal ligand-binding domain (LBD), 
specifically the Lac-repressor between the consensus and non-consensus sequences.133, 134 
DNA-ligand interaction by the process of intercalation between DNA base pairs can therefore 
be applied to the development of synthetic molecules.135 DNA bis-intercalation with binding 
to the major groove of DNA is the binding mode of the XR5944 drug, 29 which possesses 
strong anti-tumour activity (Figure 1.24).136, 137 XR5944 was formerly designed as a 
topoisomerase inhibitor,138 as it is a DNA bis-intercalating compound that has reached Phase I 
clinical trials (Figure 1.25).136, 139  
 
 















Figure 1.25:  (A) Preferred XR5944 DNA binding site on the DNA d(ATGCAT)2 hexamer. (B) Two 
binding sites of the drug XR5944 on the TFF1 ERE DNA sequences, where the weak bindings sites 
(XR1-1 and XR2-2) are displayed by the light boxes, while the strong binding sites (XR1-2 and XR2-
1) are displayed by the darkened boxes. The solid lines on the sequence represent the ERE half-sites. 
 22 
Both acridine carboxamides and phenazine carboxamides, which are known to be XR5944 
parent compounds are inhibitors of DNA topoisomerase I/II.140-142 The mechanism of action of 
XR5944 has been demonstrated by recent studies, which present that it is related to the 
inhibition of transcription as it is essentially topoisomerase independent,139, 143 although 
previous reports illustrated that XR5944 is responsible for disrupting the regular function of 































Figure 1.26:  (A) NMR spectroscopy determination of XR5944 drug equivalents from 0 (top) to 1 
(bottom) binding with d(ATGCAT)2 DNA hexamer. New DNA-Drug complex protons have started 
appearing, while the free DNA proton peaks have started disappearing according to the increased 
concentrations of XR5944. Once the XR5944 drug equivalence of 1 is reached, protons representing 
free DNA disappear entirely. (B) NOESY spectra of XR5944-DNA complex representing the expanded 
nonexchangeable regions. (1) Aromatic-H2’/H2’’/methyl region. Both the (*) and the (↑) (only for 
C4H5) symbols representing the XR5944 and DNA intermolecular NOE cross-peaks. (2) H1’ aromatic 
region. The serial assigned pathway is represented by the spectra.  
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XR5944 is considerably more efficacious than doxorubicin and topotecan topoisomerase 
inhibitors, as XR5944 has displayed remarkably strong activity against both murine and human 
tumour models both in vitro and in vivo.144, 145 XR5944 has also demonstrated strong efficacy 
both in vivo and in vitro in both; colon cancer cell lines in conjunction with irinotecan and 5-
fluorouracil146 and in non-small-cell lung carcinoma in conjunction with doxorubicin and 
carboplatin due to its DNA binding sites (Figure 1.27).137, 147 This binding mechanism involves 
the amino alkyl linker binding to DNA via major groove binding and the phenazine moieties 















Figure 1.27:  XR5944 and the 5’-TpG predominant binding site in the DNA hexamer displaying the 
intermolecular NOE cross-peaks. The solid lines represent strong intensity for NOEs, the thick dashed 














Figure 1.28:  DNA-XR5944 complex structure. The amino alkyl linker of XR5944 binds in the 
major groove of DNA, while both phenazines intercalate into DNA parallel to the base pairs in the CPK 
model displayed. 
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XR5944 can bind to number of sites on DNA forming various complexes (Figure 1.29).136 
Drug resistance is minimised with XR5944 due the suppression of ERα activities, which results 
in the inhibition of ER-ERE binding, as XR5944 binds to the oestrogen response element 
(ERE) and this also makes XR5944 a potential drug candidate for antioestrogen treatments.136 
ERE-specific bis-intercalators including XR5944 derivatives can be synthesised for specific 




















Figure 1.29:  1:1 d(ATGCAT)2-XR5944 complex displayed in (A), 2:1 TFF1-XR5944 complex 
displayed in (B) Adenine = red, thymine = blue, guanine = green and cytosine = yellow, as the XR5944 
molecules are represented by the CPK model. 1:1 d(ATGCAT)2-XR5944 complex represented by (C), 
XR1 form of attachment of XR5944 with DNA represented by (D) and the second XR2 form of 
attachment of XR5944 with DNA represented by (E) where the XR5944-TFF1 2:1 complex is formed, 
which is viewed from the major groove (left) and the minor groove (right). 
 
 
It has been determined that the binding equilibrium of XR5944 is gradually changed at pH 7 
at the NMR time scale upon binding with DNA and forming a 1:1 stable complex with 
d(ATGCAT).136 A stable duplex DNA is the result following the process of binding of XR5944 
to DNA, due to the previously unseen G3HN1 imino proton at 15°C in the free DNA, now 





WP631, 30 is another recently developed bis-anthracycline, which is a strong DNA bis-
intercalator, where both anthracycline groups slide between the DNA base-pairs.148 WP631 
demonstrates strong clinical potential, due to initial cytotoxicity studies. The induction of P-
glycoprotein causes a higher drug efflux, which results in multidrug resistance (MDR). MDR 
is well known to minimise the efficacy of various anthracyclines.149 WP631 is known to 
surpass MDR, displaying stronger cytotoxicity against MDR in human carcinoma cells than 
against sensitive cells as it bis-intercalates in the DNA hexamer duplex.148 5′-C(1)G- 
(2)A(3)T(4)C(5)G(6)-3′ on the fist and 5′-C(7)G-(8)A(9)T(10)C(11)G(12)-3′ on the second 
strand of DNA complex have demonstrated WP631 bis-intercalating between base pairs C(5)-
G(8) and G(6)-C(7) and between base pairs C(1)-G(12) and G(2)-C(11).150 The centre of the 
DNA complex has displayed the strongest bis-intercalation affinity of WP631. WP631 has 
stronger efficacy against Jurkat T-cells, MCF7/VP-16 and MCF-7 leukemia cells compared to 
mono-anthracyclines (Table 1.1).148, 151 WP631 has also demonstrated 5-8 times stronger 
efficacy hindering the Jurkat cell growth compared to daunorubicin (Figure 1.30).148, 151 
WP631 is known to bis-intercalate into DNA via its anthracycline moieties (Figure 1.31).150 
 
 
Table 1.1:  In-vitro cytotoxicity of Doxorubicin, Daunomycin and WP631. 
 
 
Figure 1.30:  The structure of this bis-daunomycin molecule, WP631. 
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Figure 1.31:  The crystal structure of the bis-daunomycin molecule WP631 bound to the duple 
sequence d(CGTACG), displaying the anthracycline groups bis-intercalating between the DNA base 
pairs. 
These modes of DNA recognition first were discovered in the early 1960s and have become 
essential in the field of DNA recognition.89 Proteins are responsible for binding in or around 
the major groove and creating specific hydrogen-bond interactions to the edges of base pairs, 
as DNA sequence recognition is accomplished.131 This is due to the groove having a larger 
variation in terms of its size and shape or a greater number of hydrogen-bond donor and 
acceptor units to which binding of the protein can take place.89 The major groove recognition 
generally refers to cylindrical alpha helix units. The units are sized and shaped to perfectly fit 
the main groove and are too large to fit in the minor groove. Helix-turn-helix structures are 
included by the motifs.152 Synthetic minor groove regulators and binders have become a 
popular topic in modern medicine as these agents have various clinical applications as they 
possess anti-cancerous, antibacterial, antiviral and protozoal properties.153 Synthetic 
bisbenzimidazoles (such as Hoechst 33258), diarylamines (including pentamidine, berenyl and 
pentamidine) and a natural molecule distamycin A are known minor groove binding agents.153 
DAPI has been thoroughly examined as an anti-parasitic agent even though its use is greatly 
limited due to toxic side effects, therefore its use is more beneficial as a blue-fluorescent stain 
for studying DNA.154 It can be easily transported through cell membranes and has proven to be 
popular in microscopic studies.155 DAPI is known to inhibit both RNA and DNA polymerase 
as it binds to the Adenine-Thymine rich regions of double-stranded DNA.154 The AT regions 
of DNA B have a smaller, narrow sulcus than the GC regions, in order for the drug can adapt 
perfectly to the sulcus walls. Synthetic molecules that affect the major DNA groove are rare. 
Their smaller size, synthetic molecules tend to collect in the small groove or between base 
pairs. Guanine-Cytosine regions of B-DNA have wider minor groove and therefore the drug 
cannot fit against the walls of the groove as opposed to Adeninde-Thymine regions which allow 
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the drug to fit perfectly against the walls of the groove.156 Synthetic molecules that are either 
intercalators or minor groove binders are more favoured over molecules that target DNA major 
groove because of their significantly smaller size.157   
The DNA transactions in vivo and in vitro are envisaged by DNA intercalators which have a 
common use as fluorescent probes.158 They are known to alter the structure and stability of 
DNA, which in turn can affect the processing of DNA by proteins.158 DNA intercalators can 
be linked reversibly between the double-stranded complimentary bases of DNA.158   
DNA-processing by proteins can be affected as a result of intercalators disrupting DNA 
structure and stability upon their attachment.158 Stabilisation, lengthening, stretching, local 
unwinding and some other structural changes in the DNA are caused by intercalation. Although 
the general form of B-DNA is preserved, the change in several biological functions results from 
intercalation.159-161 Intercalators are clinically used as anticancer, antiparasitic and antibacterial 
agents162-164 as they hinder the transcription process, growth and cell division as a result of 
suppressing DNA replication, which presents them as excellent therapeutic agents.165 The 
structure and dynamics of nucleic acids are studied from examining the mechanisms of 
intercalation agents.166, 167 Intercalation is known to generally affect cancer cells due to cancer 
cells being more susceptible to growth, although other normal cells are also affected.168 One 
family of strongly DNA binding agents via intercalation are naphthalimides due to their 
anticancer activity through photoinduced DNA damage and their inhibition of Topoisomerase 
l/ll.169 Previously developed examples of naphthalimides that have proven their efficacy 









1.8.1 Naphthalimides as intercalating DNA Binding Agents 
Napthalimides consist of a mainly π-deficient aromatic or heteroaromatic region, which is 
known to intercalate in between the base pairs of the double helix of DNA.170 Naphthalimides 
were developed as a result of a combination of structural components of a number of antitumor 
synthesised compounds which included the basic side chain of CG603 and tilorone, the 
glutarimide rings of CG603 and cycleheximide and the β-nitronaphthalene of the aristolochic 
acid.171 Stacking and charge transfer of napthalimides are the main driving forces for binding 
to the DNA.172 The change of degree of rotation between base pairs, and the distortion of the 
sugar phosphate backbone occurs due to intercalation, which is known to cause the base pairs 
to separate vertically.173 The development of bis-intercalating agents is the result of the 
therapeutic properties of these lead drugs, where two linked Naphthalimides create more 
possibilities of limiting cytotoxicity and side effects after administration.174 The derivatives of 
1,8-Naphthalimides are effective in a range of applications in medicine due to their strong 
photostability, electroactivity and fluorescence, as these types of compounds are used as dyes 
for polymeric matierials,175-177 chemiluminescent agents178 as well as synthetic and natural 
fibres.175, 179, 180 A number of derivatives of naphthalimides have also been described as 
molecular probes.181, 182 Due to their unique properties, naphthalimides have found application 
in many areas of chemistry, for example in fluorescence sensors, dyes, chemical probes, in the 
detection of biologically relevant cations and anions, and in pharmacy as cancer treatment 
(Figure 1.32).183-185 It is widely acknowledged that the cytotoxic properties of various 
substituted Naphthalimides have significant antitumor activity.182 DNA photocleavage is 
known to result from a number of reactive intermediates as a result of inhibition of both DNA 
and RNA synthesis, due to the reading errors in the course of the replication process, as a result 
of an enzymatic restriction caused by the process of DNA intercalation by the naphthalimide 













Figure 1.32:  Uses of various naphthalimides in different binding modes to DNA.188 
 
 
All clinical trial studies have been abandoned due to toxic side effects of napthalimides, 
although a number of its derivates have been approved for clinical trials.189-193 Various changes 
in the structures of naphthalimides have been made in recent years as several derivatives with 
different cycle substitutes, side chains and aromatic ring systems were synthesized, to reduce 
side effects and enhance antitumor activity.194-197 Naphthalimide dimerisation is a design in 
which derivatives of 1,8-napthalimides display higher anti-tumour activity in human 
xenographs, as elinafide (bis-intercalator) has a higher activity compared to monomers and it 
is therefore a commonly practiced design.198 Among all sorts of spacers, except Tröger’s base 
moieties,199-204 Lin et al. have studied a spermidine-bound bis-naphthalimide derivative and it 
had displayed an IC 50 value of 0.15 and 1.64μM for the adenocarcinoma cells HT-29 and 
Caco-2 in the large intestine and caused intense DNA damage.205 This compound also 
displayed an increase in fluorescence upon DNA binding. Intercalators such as 
bisphenanthridine, bisnaphthalimides and bisphenanazine carboxamides, which are dimers, 
have also showed a strong anti-tumour potential.  The in vivo activities of bis-naphthalimide 
drugs such as WP631206 and bisnafide207 have accelerated the research synthesising new bis-
intercalators as DNA binders. The main reason behind the synthesis of dimers is to improve 
DNA binding affinity and sequence recognition.  In some cases, nonetheless, the second 
 30 
chromophore can serve as a hook to capture cofactors and proteins that bind to DNA but it does 
not act as an intercalator.208 The 1,8-naphthalimide derivatives generally show very strong 
fluorescence and they are universally used as dyes in the polymer industry, fluorescent probes 
for medical and biological purposes as fluorescent cell markers, n-type materials in the organic 
light-emitting diodes,209 anti-HIV drugs and DNA cutting agent, laser dyes and crystal 
additives.209 The excellent properties in terms of fluorescence of the commercially available 
compounds of 1,8-naphthalimide rely heavily on the presence of alkoxy and alkylamine groups 
at the C-4 position, which are known as strong electron donating groups.210 As the derivatives 
of naphthalimides are one of the best examined fluorescent probes owing to their brilliant 
photophysical properties, these fluorophores are frequently tested in the biological and 
biochemical disciplines.211 DNA plays an important role in everyday life and consequently this 
macromolecule continues to be one of the main molecular targets in the design of antineoplastic 
agents as naphthalimides are effective intercalators with DNA base pairs and this makes them 
of the strongly active anticancers drugs.188 Amonafide, a novel topoisomerase ll inhibitor was 
first developed almost 40 years ago.212 As an evidence of marked antineoplastic efficacy in 
preclinical trials of cancer, the drug was selected for further investigation and testing due to its 
ability to form a ternary drug-DNA-topoisomerase complex, with the side chain interacting 
with the enzyme of the DNA and the planar ring interacting with the DNA/protein interface.213 
Amonafide, 31 had specifically been used against secondary treatment-associated acute 
myeloid leukemia (AML), as amonafide was resistant to Pgp-mediated efflux mechanisms, as 
Between 50 and 70% of blasts examined from treatment-resistant, relapsed and secondary 
AML (sAML) were found to be positive for Pgp,214, 215 as its usefulness in the treatment of 
various solid malignancies proved limited.193 After Phase I studies of amonafide in solid tumors 
identified myelosuppresion as the most significant dose-limiting toxicity (DLT).216 Mitonafide, 
32 intercalates the double stranded DNA, it induces single strand breaks in DNA and hinders 
the incorporation of DNA precursor into the acid-soluble fraction.217 Mitonafide is known to 
induce specific DNA cleavage at a single major site on pBR 322, while it also stabilises a 
reversible enzyme-DNA as it is a topoisomerase II inhibitor.218 Mitonafide has shown in vitro 
toxicity against cells such as KB cells, HeLa cells and other tumoral cell lines, while also 
showing an in vivo antineoplastic activity against L1210 and P388 leukemias, Lewis lung 
carcinoma, rat Yoshida carcinoma and Erlich ascites carcinoma.207, 217 Elinafide, 33 differs 
from both amonafide and mitonafide as it is a bis-napthalimide (contains two naphthalimide 
groups) had been tested in a number of tumours including breast cancer, and mesothelioma, 
breast cancer and ovarian cancer,219 as it had shown partial regressions or complete regressions 
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inLOX (melanoma), CX-1 (colon), LX-1 and DLD (colon) xenografts.174 Elinafide is 
responsible for bis-intercalating DNA via the major groove, where bis-intercalating is a process 
of intercalation using two links, or a double bond.220, 221 Elinafide treatment had resulted in 
tumour regression and tumour growth inhibition and even tumour free survivors in a number 
of these models.219 Elinafide is known to form a complex that is sequence-specific which 
includes the hexanucleotide d(ATGCAT)2, where two naphthalimide groups bis-intercalate 
with the DNA molecule.219 In vivo, Elinafide is very effective against tumour xenographts, as 
tumour xenographts are models of cancer where the cells or tissues from a  tumour of a patient 
are introduced into an immunodeficient or humanised mouse.198 One of the striking differences 
between Amonafide and Mitonafide compared to Elinafide is the inclusion of a second 
naphthalimide moiety: so-called bis-naphthalimides (Figure 1.33).196, 222 A number of bis-
naphthalimides have been reported, where they show strong DNA binding ability coupled with 
high cellular cytotoxicity.203  
 
 
Figure 1.33:  Chemical structures of mono-naphthalimide derivatives: Amonafide, Mitonafide and a 
bis-naphthalimide derivative: Elinafide. 
 
1.8.2 Bis-Naphthalimides as intercalating DNA Binding Agents 
A recently reported example of bis-naphthalimides containing a Pt(II) linker, 34 and 35 display 
high cytotoxicity against MCF-7 breast cancers, while having strong binding ability due to 
Pt(II) additionally binding to the negatively charged sugar phosphate backbone via electrostatic 





Figure 1.34:  Pt(II) bis-naphthalimide family of compounds, which display stronger cytotoxicity 
and DNA binding over cisplatin in MCF-7 breast cancer cells. 
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These agents also display excellent results in minimising resistant cisplatin-resistant cells 
lines.190 Transition metal complexes have sparked a lot of interest in recent years as 
chemotherapeutic anti-cancer agents in recent years.223 Perez et al. have synthesised various 
novel Pt-bis naphthalimide conjugates in order to minimise cellular resistance, while enhancing 
cytotoxicity and DNA binding ability via bis intercalation (from both naphthalimide groups) 
and platinization of DNA bases by Pt(II).224 Both 4-N,N-dimethylamino-1,8-naphthalimide 
and terpyridyl are incorporated by the Pt(II) based bifunctional DNA binder, recently 
synthesised by Banerjee et al., displaying stronger (IC50 18 mM) toxicity against MCF-7 
breast cancer cell lines and stronger DNA binding affinity in comparison to the commercially 
available cis-platin.225 
 
Due to the kinetic and chemical inertness, water solubility and spectroscopic properties such 
as photoluminescence and visible light absorbance, Ru(II)-polypyridyl complexes demonstrate 
their uses in modern therapeutic treatments.44, 226, 227 These complexes have displayed their 
internalisation mechanisms via passive diffusion, endocytosis and active transport, as well as 
via the use of polypeptides for cell internalisation.228-238 Electrostatic interactions, intercalation, 
and groove binding are examples of modes of Ru(II)-polypyridyl binding to DNA.44 Both 
Ru.Nap, 36 and Ru.2Nap, 37 have strong DNA binding properties due to their CD activity in 
the presence of DNA (Figure 1.35).239 
 
Figure 1.35:  Chemical structures of DNA binders: Ru.Nap and Ru.2Nap. 
 
 
The naphthalimide moiety of 36 displayed binding to DNA via the process of intercalation, 
proven by the substantial  negative band in the LD.239 Proven by the small LD signal of the 
naphthalimide region, 37 had displayed binding to DNA in a more complex way. Both 
naphthalimide regions of 37 have intercalated into DNA, which caused the Ru(II)-polypyridyl 
centre shift in its position at the negatively charged DNA sugar phosphate backbone.239 
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Compound 37 had displayed poor cleavage of plasmid DNA upon light activation when 
compared to 36. Compound 37 was nontoxic when introduced to HeLa cells, as it had 
significantly reduced viability of the HeLa cell after photoactivation.239 It was concluded that 
the presence of a second naphthalimide strengthened the binding ability of 37 compared to 
single naphthalimide moiety in 36, while not increasing its toxicity and this information is 
detrimental as such complexes have the potential for the uses as therapeutic agents.239 This 
creates the possibility to use a different linker in potential bis-naphthalimide agents, which has 
the ability to bind to the negatively charged sugar phosphate backbone of DNA. One method 
of conjugation that has garnered significant interest recently is the use of the squaramide moiety 
to act as a linker between two molecules. With excellent H-bonding ability coupled with 




























Squaramides, a family of cyclic derivatives of the rigid form of cyclobutene, are rapidly gaining 
interest in research in various fields of chemical and biological science.240-243 This small 
molecular scaffold consists of two carbonyl hydrogen bond acceptors close to two N-H 
hydrogen bond donors and benefits from unique physical and chemical properties that make it 
exceptionally useful in various areas such as self-assembly, catalysis, bioconjugation and 
molecular recognition.240 The process of delocalisation of a nitrogen lone pair in the 
cyclobutenedione ring system, gives the four-membered ring its aromatic character (Huckel's 
rule: electrons [4n + 2] p, n = 0).241 Furthermore, the ability of squaramides to form strong 
hydrogen bonds that simultaneously improve the aromaticity of the four-membered ring is 
extremely beneficial, as the molecular recognition and self-assembly processes can take 
advantage of the thermodynamic stability caused by the aromatic gain.244, 245 Squaramides are 
predominantly known to be favourable in asymmetric synthesis as chiral ligands and H-binding 
catalysts,246-249 but are also very useful as building blocks in the field of medicinal chemistry. 
Navarixin (chemokine receptor antagonists 1 and 2)250 and Perzinfotel (NMDA receptor 
antagonist)251 are examples of small molecules with an embedded squaramide structure that 
have reached the various stages of clinical studies. One of the main reasons why squaramides 
are considered as a motif of interest is due to their ability to donate H-Bonds to various 
functional groups such as ureas, amino and carboxillic acids, cyanoguanidine, guanidine and 
various phosphate groups make squaramides very attractive in medicinal chemistry.241 In the 
recent years, derivatives of mono- and bis-squaramides have been studied for the treatment of 
Malaria,252 Chagas disease253 and Leishmania,254 which are diseases transmitted by insects. A 
high affinity for hydrogen bonding is caused by a simultaneous increase in the aromaticity of 
the cycle. This hydrogen bond and aromatic change in combination with structural rigidity has 
been used in many Squaramide applications.241 The simultaneous gain of the aromaticity of the 
ring causes strong hydrogen bonding affinity and this enabled the use of this aromatic change 
and aromatic switching together  with structural rigidity has been used in many squaramide 
applications.241 In a series of articles, Deya, Frontera and their colleagues have examined the 
physical properties of squaramides and their derivatives with cations and anions.241 It was 
acknowledged that secondary squaramides provide donors, acceptors and donor-acceptor 
groups with a high possibility of forming hydrogen bonding to acceptors suaramides.241 An 
investigation of the configuration of artificial squaramide receptors for the detection of cations 
has shown that squaramide receptors have a strong acceptance of hydrogen bonds in the 
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detection of ammonium ions.241 It has been shown that the excellent hydrogen bonding and 
acceptance of squaramides (Figure 1.36)241 can be described by an improvement in the 








Figure 1.36:  Squaramides displaying the ability to act as hydrogen bond donors-acceptors in both 
anti/anti and anti/syn configurations.  
 
Hence, squaramides have been utilised as an alternative to (thio) urea in the process of 
organocatalysis.256 The process of self-aggregation of squaramides generates low solubility and 
thus possible precipitation, which is created by a multitude of links from head to tail via double 
hydrogen bonds.257 Low solubility of squaramides in non-polar solvents, reduced the ability to 
regulate the pKa of the donor hydrogens and the limited solubility in non-polar solvents restrict 
the performance in a  number of reactions.257 
 
Recently, the area of anion detection has grown significantly, and much research has been 
performed in the field of anion sensors,258, 259 anion receptors.260 The first revolutionary work 
by Costa and colleagues in the field of anion detection with squaramides261, 262 was followed 
by a report by Fabbrizzi et. al, in which the ability to detect urea anions was compared with a 
squaramide which had identical aromatic substituents.255 
 
Numerous biological processes are dependent on the process of molecular recognition between 
a substrate and the associated enzyme.263 Hydrogen, π-π, cation-π, and anion-π, van der Waals, 
hydrophobic and electrostatic interactions are responsible for holding substrates with the 
associated enzymes.264 Derivatives of squaramides have been precisely studied as receptors for 
numerous anions including: sulphate,246 chloride,241 benzoates265 and carboxylates241 due to the 

























Figure 1.37:  Squaramides displaying their ability in various beneficial applications. 
 
While the use of squaramides has attracted a lot of research attention in recent years, they have 
not yet been exploited in the field of DNA recognition. Given their known ability to bind to 
anionic species, this is surprising, particularly given the anionic nature of the DNA-phosphate 
backbone. This project will aim to explore the potential of squaramides to improve DNA 
binding ability, specifically in this case taking advantage of the naphthalimide moiety. The 
















1.10 Aims and Objectives 
As part of this project, we aim to design and synthesise a range of squaramide based bis-
naphthalimides (Figure 1.38). The general design strategy is outlined as a schematic in Figure 
1.38. This will include a central squaramide unit conjugated to two naphthalimide units via 
aliphatic linker. Two main variables will be introduced, whereby the linker length will be 
varied from 2 carbons to 8 carbons. Similarly, the orientation and substitution pattern of the 
naphthalimides will be varied to provide a range of photophysical properties and DNA binding 
characteristics. Given the ability of Elinafide to bind strongly to DNA, we expected that the 
inclusion of a squaramide moiety would improve DNA binding ability given its known 
propensity for strong H-bonding. This is particularly important given the negatively charged 
sugar-phosphate DNA backbone. We will synthesise a series of bis-naphthalimides, where we 
will vary the linker length that separates the squaramide (H-bonding ability) from the 
naphthalimides (intercalation). This creates the possibility that the bis-naphthalimide linker 
will bind to the negatively charged sugar phosphate backbone of DNA via hydrogen bonding, 
while the naphthalimides will engage in DNA intercalation.  
 
 
We have designed compounds 38-46 (Figure 1.39), a family of squaramide-naphthalimide 
conjugates, where both the linker length and substitution pattern of the naphthalimide will be 
varied. Elmes et. al have previously synthesised a series of naphthalimide-squaramide 
conjugates that efficiently assembled in solution, where self-assembly was reversed as soon as 
the H-bonding network was disrupted by anion addition.266 The squaramide position relative 
to the naphthalimide was varied at either the head or the tail of the structure, as the design 
included a short linker with a strongly hydrophobic side arm, which was believed to support 
the sensor’s aggregation behaviour in polar solvents.267 These important results will be used to 
inform experimental design for this project. 38-40 are composed of naphthalimides without 
substitution, this was chosen for the ease of synthesis and also the observing the fluorescent 
properties, DNA binding properties and the possibility of synthesis of substituted 
naphthalimides, where 41-43 contain an amino naphthalimide. The 4-amino naphthalimide was 
 
Figure 1.38:  General schematic of proposed synthetic compounds. 
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chosen as this substitution of naphthtalimide describes the possibility of an increase in emission 
an important consideration, when designing squaramide containing bis-naphthalimides. Upon 
binding to DNA, it is expected that these compounds would be strongly fluorescent prior to 
DNA interaction, with a large shift in fluorescence change after DNA interaction, enabling the 
determination of DNA binding due to this change in emission. Thirdly, 44-46 included an 
alternative attachment point to the naphthalimide, where the linker was incorporated at the 4-
carbon position. It was expected that this may affect the DNA binding properties for these 
conjugates, as Gunnlaugsson et al. previously reported the importance of the substitution of 
the tail-to-head attachment of naphthalimides.268 
 
Once successful synthesis and characterisation has been carried out, we will investigate the 
















Chapter 2 Synthesis   
2.1 Introduction  
As discussed in the previous chapter, naphthalimides are a class of polycyclic imides that 
comprise of π-deficient planar aromatic or heteroaromatic ring systems.188 1,8-naphthalimides 
and their derivatives have displayed excellent physicochemical and biological properties. Most 
of 1,8-naphthalimides display a broad range of biological activities as they show strong 
antiviral, antibacterial and anticancer activity.171 1,8-Naphthalimides are especially known to 
inhibit tumour growth and tumour metastasis, due to their strong DNA intercalation.188 For 
instance, as previously discussed in Chapter 1, Elmes et al. reported a group of naphthalimide-
based ruthenium compounds as DNA binders. The scientific community has made several 
attempts to enhance the naphthalimide moieties to promote their DNA antitumor and 
photocleaving abilities, by synthesising bis-naphthalimides which increase their DNA binding 
ability.174, 222, 269 Naphthalimides have found application in a variety of areas of chemistry, from 
their use as anticancer, antiviral, anti-inflammatory, antiprotozoal and antidepressant agents to 
novel DNA intercalators in medicinal chemistry.171 Research by the Elmes group has focused 
on the development of squaramide-naphthalimide scaffolds with potential applications in a 
variety of biomedical and anticancer treatments.240 The aim of this chapter is to synthesise 
squaramide, bis-naphthalimide conjugates, which were varied in the aliphatic chain lengths and 
electron donating group presence, squaramide absence in a bis-naphthalimide and squaramide 
absence in a mono-naphthalimide. Below, we will outline the synthetic approach to make 
compounds 38-46 using various known and new synthetic transformations.  
 
2.1.2 Varying the linker 
Three different lengths of linkers (2-carbon, 5-carbon and 8-carbon) were exploited in the 
design of the novel squaramide-naphthalimide conjugates (Figure 2.1). A 2-carbon linker was 
introduced into the design of the novel compounds to promote potential stacking interactions 
via increased structural rigidity, which is ascribed to the reduced degrees of rotation by the 
presence of the two carbon groups. The linker of 5-carbons was introduced into the design of 
the novel compounds to act as a comparison for the linker containing 2-carbons, which is more 
prone to aromatic stacking. The main objective was observing whether the bis-intercalation 
into DNA by the naphthalimide motifs of the molecule were more intense, due to the varied 
lengths of the aliphatic moiety. The linker of 8-carbons was synthesised to observe whether 
this squaramide-naphthalimide conjugate is even more likely to bis-intercalate into DNA, due 
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to its longer distance from the squaramide motif compared to the previously synthesised 2-
carbon and 5-carbon length squaramides. 
 
Figure 2.1:  Structure of linkers exploited in the design of the potential bis-intercalators.  
 
2.1.3 The squaramide motif 
Squaramides have the capacity for selectively binding into the negatively charged sugar 
phosphate backbone of DNA via their acidic N-H groups resulting in the formation of H-
bonds.240, 266 Squaramide scaffolds have the ability to undergo 𝜋-𝜋 interaction between the 
cyclobutenedione rings, due to their properties of aromaticity and planarity.240 In the design of 
our novel squaramide-naphthalimide conjugates, we foresaw the 𝜋-𝜋 interaction between the 
cyclobutenedione rings. We have also foreseen the remarkable hydrogen bonding donor ability 
of the squaramide motif could be utilised to use these squaramide-naphthalimide conjugates as 
DNA binders. 
 
2.1.4 Varying the Substitution Patterns 
These reports indicate that 1,8-naphthalimide derivatives are not only capable of cleaving DNA 
photochemically but that, depending on the substitution pattern, hydrogen abstraction atoms 





2.1.5 The Binding Site Position 
In the design of our novel squaramide-naphthalimide conjugates (Figure 2.2), we envisaged to 
synthesise squaramide-naphthalimide conjugates with a non-substituted naphthalimide, 4-nitro 
bis-naphthalimide to yield the desired 4-amino bis-naphthalimide. The fluorescence properties 
of naphthalimides can also be modulated by the nature of the substitution pattern. This 
substitution was varied due to the synthetic pathway leading to the synthesis of the 4-nitro bis-
naphthalimide derivatives, which are not fluorescent due to the electron withdrawing nitro 
group presence. These compounds will be further reduced into the 4-amino bis-naphthalimide 
derivatives, with an electron donating group. 4-amino bis-naphthalimides are known for their 
strong emission and fluorescence properties. These compounds have strong green-fluorescence 
properties and after intercalation into DNA, their fluorescence undergoes a red-shift.270 This 

























Figure 2.2:  (A) Structures of target compounds with unsubstituted, electron withdrawing and 







2.2 Synthesis  
The target compounds 38-40, 47-49, 97 and 98 were synthesised from commercially available 
starting materials. All intermediate and target compounds were fully characterised using 1H 
NMR, 13C NMR, high resolution mass spectrometry and infrared spectroscopy. In this chapter, 
the description of the synthesis and characterisation of each synthesised compounds 38-40, 47-
49, 97 and 98 and the attempted syntheses of compounds will be given.  
 
The proposed synthetic pathway will firstly involve the mono-boc protection of the aliphatic 
linker, followed by the reaction with naphthalene-1,8-dicarboxylic anhydride, which will be 
deprotected with trifluoroacetic acid in dichloromethane and the resulting trifluoroacetic salt 
will be reacted with diethyl squarate to yield the desired compounds 38-40 (Figure 2.3).  
 
 
Figure 2.3: Initially proposed synthetic pathway of compounds 38-46. 
 
 
2.2.1 Synthesis of 50 
The synthesis of diethyl squarate, 50 (See Appendix) was achieved using intermediates in the 
synthetic pathway as outlined in scheme 2.1. 3,4-dihydroxycyclobut-3-ene-1,2-dione was 
dissolved in ethanol followed by an instant addition of triethylorthoformate. The mixture was 
allowed to reflux at 85°C for 48 hours.273 The product was concentrated in-vacuo to afford the 
crude material. The desired product was purified via column chromatography to afford a yellow 





Scheme 2.1: Synthesis of 50.  
i) Triethylorthoformate, ethanol. 
 
2.2.2 Synthesis of 51, 52 and 53 
The next step involved synthesising aliphatic linkers of appropriate lengths. The syntheses of 
compounds 51, 52 and 53 involved a mono-boc protection of ethane-1,2-diamine, pentane-1,5-
diamine and octane-1,8-diamine by a dropwise addition of di-tert-butyl dicarbonate, while 
allowing it to stir at 0°C for 3 hours.274 After letting the reaction reach room temperature 
overnight while stirring, the mixtures were each washed with water and with brine, dried over 
MgSO4 and the products were concentrated in-vacuo to afford a colourless oil in all three cases. 
The afforded yields in all three reactions were 90% for 51, 85% for 52 and 91% for 53.  
 
Scheme 2.2:  Syntheses of 51, 52 and 53.  
ii) Chloroform, di-tert-butyl dicarbonate.  
 
2.2.3 Synthesis of 54, 55 and 56. 
Naphthalene-1,8-dicarboxylic anhydride was dissolved in toluene with triethylamine. The 
appropriate diamines were all added into each separate reaction. All three reactions were 
allowed to reflux at 125°C for 12 hours accordingly following the standard method.275 The 
reaction times were also monitored by TLC and 1H NMR analyses. The solvent was removed 
in-vacuo to afford the crude products. The desired products were purified via column 
chromatography to afford white solids 54, 55 and 56 with yields of 89%, 84% and 77%. 1H 
NMR analysis of 54 (Figure 2.4) had further confirmed the purity of the compound, where the 
naphthalimide moiety was represented by the signals at 8.49, 8.45 and 7.87 ppm, while the N-
H was represented by a signal at 6.88 ppm, the aliphatic CH2s were represented by the signals 
at 4.14 ppm and 3.25 ppm and the boc-protecting group was represented by the singlet signal 
0°C 
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at 1.02 ppm. Similar results were obtained for 55 and 56 with only additional aliphatic CH2 
signals (2.0-5.0 ppm) depending on the length of the aliphatic chain for each compound. 
 
Scheme 2.3: Syntheses of 54, 55 and 56.  
iii) Ethanol, triethylamine, naphthalene-1,8-dicarboxylic anhydride  
 
Figure 2.4:  The 1H NMR Spectrum of 54 (500 MHz, DMSO-d6, 298 K.)   
 
 
54, 55 and 56 were each dissolved in dichloromethane and trifluoroacetic acid (50:50). All 
three reactions were allowed to stir at room temperatures. The reduction of 54 required 2 hours 
to form the product TFA salt 57. The reduction of 55 required 3 hours to form the product TFA 
salt 58 and the reduction of 56 to form the product TFA salt 59 required 12 hours. The solvent 
was removed with N2 and in-vacuo. The title compounds appeared as brown residues in all 
three cases and were used directly without further purification closely mirroring the reaction 
done previously by Kamal et. al.276 The LCMS (Figure 2.5) demonstrated the purity of 57, with 
a single peak of the compound, without any other impurities, where the TFA peak is not 




Scheme 2.4: Syntheses of 57, 58 and 59.  
iv) Dichloromethane, trifluoroacetic acid 
 
Figure 2.5:  LCMS Characterisation of 57: (a) Analytical HPLC trace of purified 57; Rt = 3.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 241.26 [M + H]+. (c) 
Mass Spectrum detected between Rt = 3.0-4.0 mins (157 scans); Calculated for [M + H]
+ = 241.3; Mass 
Found (ESI+) = 283.1 [M + MeCN+H+H]+.  
 
It was theorised that once 57, 58 and 59 were each dissolved in ethanol first and the solvents 
mentioned were added after using ethanol with a slow addition of 50, the desired products 
would be achieved, as previously done with naphthalimide urea derivatives.275 Triethylamine 
was added in all three reactions until completely dissolved. 50 was added into the reactions 
individually. All three reactions were allowed to reflux at 85°C for 12 hours. The reactions all 
formed precipitates, which were filtered and centrifuged in ethanol and diethyl ether. 
Unfortunately, upon NMR analysis (Figure 2.6), it was clearly observed that the precipitates 






Scheme 2.5: Syntheses of 60, 61 and 62. 
v) Triethylamine, 3,4-diethoxycyclobut-3-ene-1,2-dione, Attempted to synthesise the target 
compounds in Ethanol first and after numerous failed attempts: Methanol, Toluene, 
Dichloromethane, Dimethylformamide,  Tetrahydrofuran have been used, similarly done in the 






Figure 2.6: The 1H NMR Spectrum of 60 (500 MHz, DMSO-d6, 298 K.) 
 
1H NMR analysis of 60 (Figure 2.6) had further confirmed the mono-substitution of the starting 
materials, where the naphthalimide moiety was represented by the signals at 8.56, 8.51 and 
8.09 ppm, while the N-H was represented by a signal at 8.63 ppm, the aliphatic CH2s were 
represented by the signals at 4.05, 1.71 and 1.60 ppm, while the methyl CH3 region was 
represented by the singlet signal at 1.25 ppm. Similar results were obtained for 61 and 62 with 
only additional aliphatic CH2 signals depending on the length of the aliphatic chain for each 
compound.  
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The challenges encountered, when reacting 57, 58 and 59 with 3,4-diethoxycyclobut-3-ene-
1,2-dione resulting in 60, 61 and 62 due to these compounds forming a precipitate when the 
squaramide became mono-substituted. Despite several unsuccessful attempts at this approach, 
it was evident that a different approach of synthesis had to be explored.  
Throughout the synthesis of the target compounds, we encountered challenges. The main 
challenges faced were: solubility of intermediates, purification of both intermediates, target 
compounds and reduced reactivity of the starting materials. We therefore proposed to change 
the synthetic pathway. The new proposed synthetic pathway entailed the mono-boc protection 
of the aliphatic linker, followed by the reaction with diethyl squarate to form the di-substituted 
derivative. This was followed by the deprotection and the final reaction with the naphthalene-




Figure 2.7: Novel proposed synthetic pathway of compounds 38-46. 
 
2.2.4 Synthesis of 63, 64 and 65 
Scheme 2.6: Syntheses of 63, 64 and 65. 




The following steps involved the conjugation of the various linkers to the central squaramide 
moiety. The syntheses of 63, 64 and 65 involved dissolving 51, 52 and 53 respectively in 
ethanol, followed by a dropwise addition of 3,4-diethoxycyclobut-3-ene-1,2-dione  and 
allowing the mixtures to reflux at 85°C for 12 hours. The products were concentrated in-vacuo 
to afford the crude material. 63 and 64 title compounds were purified via column 
chromatography to afford two products which appeared as white solids with yields of 88% and 
81% respectively, while 65 had precipitated when the reaction had undergone completion and 
was isolated by filtration with a yield of 79%. The 1H NMR of compound 63 is shown in Figure 
2.8 as an example. As can be seen, the broad singlet at 7.5 ppm indicates the presence of an N-
H of the squaramide moiety, while the peak at 6.9 ppm indicated the presence of another N-H, 
which was assigned to the boc protecting group. There was a signal integrating to two at 3.5 
ppm, which was indicative of aliphatic CH2 next to the squaramide, while another signal 
represented two protons at 3.1 ppm which was indicative of the aliphatic CH2 next to the boc-
protecting group, which integrated to nine at 1.3 ppm. LCMS analysis was also conducted 
(Figure 2.9), which displayed a presence of a single compound and with hits for [M+H]+ and 
[M+Na]+, confirming both the purity and the identity of our proposed compound. 
 
 









Figure 2.9:  LCMS Characterisation of 63: (a) Analytical HPLC trace of purified 63; Rt = 15.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 398.46 [M + H]+. (c) 
Mass Spectrum detected between Rt = 14.6-16 mins (157 scans); Calculated for [M + H]
+ = 399.4; Mass 
Found (ESI+) = 399.1. Also Found 421.1 [M + Na]+.  
 
2.2.5 Synthesis of 66, 67 and 68 
 
Scheme 2.7: Syntheses of 66, 67 and 68. 
vii) Dichloromethane, trifluoroacetic acid 
 
The syntheses of 66, 67 and 68 involved dissolving 63, 64 and 65 in dichloromethane. 
Trifluoroacetic acid was added into all three mixtures respectively, while they were allowed to 
stir at room temperatures for 2, 5 and 12 hours respectively, as previously done with 
naphthalimide urea derivatives.275 The solvent was evaporated with N2 and in-vacuo. The title 
compounds appeared as brown residues in all three cases and were used directly without further 
purification. The LCMS (Figure 2.10) demonstrated the synthesis of 67, with a single peak of 
the compound, without any other impurities, where the TFA peak is not observed due to TFA 











Figure 2.10:  LCMS Characterisation of 67: (a) Analytical HPLC trace of 67; Rt = 3.0 mins (0-100% 
MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 283.34 [M + H]+. (c) Mass 
Spectrum detected between Rt = 3.0-4.0 mins (157 scans); Calculated for [M + H]
+ = 283.34; Mass 
Found (ESI+) = 283.1.  
 
2.2.6 Synthesis of 38, 39 and 40  
 
Scheme 2.8:  Syntheses of 38, 39 and 40. 
viii) Ethanol, triethylamine, naphthalene-1,8-dicarboxylic anhydride 
 
Having successfully synthesised 66, 67 and 68, the final step was to incorporate the 
naphthalimide structure to synthesise compounds 38, 39 and 40. The syntheses involved 
dissolving naphthalene-1,8-dicarboxylic anhydride with triethylamine respectively in ethanol. 
66, 67 or 68 were added into all three reactions accordingly, once the starting materials had 
completely dissolved. The reaction was allowed to reflux at 85°C for 12 hours. The title 
compounds appeared as precipitates with yields of 84% for 38, 89% for 39  and 77% for 
40. The afforded precipitates were purified via trituration and centrifuging in ethanol and 





an example. As can be seen from Figure 2.11, the 1H NMR of compound 38 was poorly 
resolved and resulted in broadening of all peaks. This is an indication that self-assembly 
behaviour may be occurring under these conditions. In order to probe whether this was the 
case, a series of VT-NMR experiments were also conducted, which will be further discussed 
in Chapter 3. As can be seen, the peaks at higher temperature became more 
clearly resolved with increasing temperature indicating some degree of self-assembly. 
Importantly, upon cooling of the NMR sample, peak broadening was again observed 
suggesting that this process is reversible. As can be seen in Figure 2.12, 13C NMR also 
confirmed the presence of the final compound according to peaks at 183.3 ppm, which is 
indicative of a carbonyl carbon on the squaramide moiety and 168.6 ppm and 164.0 ppm, which 
indicate the carbonyls on the naphthalimide moiety with peaks representing both the aliphatic 
region (49.0 and 19.0 ppm) and the naphthalimide region (122.0, 127.4, 127.8, 131.0, 131.5, 
134.6 ppm). The purity of the compound was also confirmed by the LCMS analysis (Figure 
2.13).  Similar behaviour was seen in all cases for compounds 38-40 (See Appendix). As 
compounds 38-40 were novel final compounds, their self-assembly and DNA binding 
characteristics will be discussed in the following chapters. 
 
 
Figure 2.11:   The 1H NMR Spectrum of 38 (500 MHz, DMSO-d6, 298 K.)  
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Figure 2.12:  The 13C NMR Spectrum of 38 (126 MHz, DMSO-d6, 298 K.) 
 
 
Figure 2.13:  LCMS Characterisation of 38: (a) Analytical HPLC trace of purified 38; Rt = 25.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 559.0 [M + H]+. (c) 
Mass Spectrum detected between Rt = 24.0-26.0 mins (157 scans); Calculated for [M + H]
+ = 559.5; 
Mass Found (ESI+) = 559.0 [M+H]+.  
 
2.2.7 Synthesis of 41, 42 and 43 
The next step of the synthesis was to obtain the 4-amino derivatives of squaramide containing 
bis-naphthalimides, which involved synthesising compounds 47, 48 and 49. This involved 






will involve 4-nitronaphthalene-1,8-dicarboxylic anhydride, which will yield 4-nitro 
derivatives of the squaramide containing bis-naphthalimides, which we hope to reduce into the 
4-amino forms via reduction reactions (Figure 2.14).   
 
 
Figure 2.14: First synthetic pathway to obtain 41, 42 and 43. 
 
 
Scheme 2.9: Syntheses of 47, 48 and 49.  
ix) Ethanol, triethylamine, 4-nitronaphthalene-1,8-dicarboxylic anhydride 
 
The syntheses of 47, 48 and 49 involved dissolving 4-nitronaphthalene-1,8-dicarboxylic 
anhydride in all three cases and fully dissolving 66, 67 and 68 separately in ethanol. Once 
dissolved, triethylamine was added into all three reactions individually. The reaction was 
allowed to reflux at 85°C for 12 hours. The title compounds appeared as orange precipitates 
with crude yields of 86% for 47, 88% for 48 and 79% for 49. The precipitates were purified 
via trituration and centrifuging in ethanol and diethyl ether. HRMS data suggested that all 
compounds were successfully synthesised. However, the characterisation data for each 
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compound was difficult to obtain due to insolubility issues. The 1H NMR of compound 47 is 
shown in Figure 2.15.  
 
As can be seen, we clearly demonstrated the correct signals for the aliphatic region and the 
naphthalimide region. However, it was difficult to draw firm conclusions based on the level of 
purity as we were unable to obtain pure LCMS and the NMR was inconclusive. Unfortunately, 
reliable purity information could not be obtained by LCMS due to insolubility in all suitable 
mobile phases. Due to the difficulties in characterisation, we decided to continue with the 
synthesis. 1H NMR of compound 47 is shown in figure 2.15. As can be seen, the signals were 
in the correct range of chemical shifts. However, at room temperature all peaks were poorly 
resolved as previously observed for compounds 38-40. VT-NMR studies were again carried 
out and improved resolution considerably (Figure 2.16). Due to overlapping signals in the 
aromatic region, full assignment of all signals was not possible. Similarly, reliable purity 
information could not be obtained by LCMS due to insolubility in all suitable solvents (Figure 
2.17). The HR-MS however did indicate the presence of 47 (Figures 2.18 and 2.19) Given the 
limited characterisation, we decided to continue with the synthesis regardless, in the hope that 
reduction of the NO2 to NH2 may result in improved solubility. The following section describes 
the attempted syntheses of compounds 41-43.  
 
 






Figure 2.16:  The 1H NMR Spectrum of 47 at 358 K (500 MHz, DMSO-d6, 358 K.) 
 
Figure 2.17:  LCMS Characterisation of 47. 
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Figure 2.19:  HRMS spectrum of 47. 
 
 
Multiple attempts to synthesise 41, 42 and 43 were made. 47, 48 and 49 were dissolved in 
ethanol, while 20% palladium on carbon was added into each reaction. More solvent was added 
to prevent 47, 48 and 49 from precipitating. However, in each case 47, 48 and 49 had 
precipitated no matter how much solvent was added into each reaction. The solvents were 
removed via Büchner filtration after 12 hours. The precipitates were analysed by 1H NMR and 
LCMS and it was concluded that the reaction had not proceeded in each case. 
 
Scheme 2.10: Attempted syntheses of 41, 42 and 43. 





























Figure: Zoomed Compound spectra view 
(red boxes indicating expected theoretical isotope spacing and abundance)








Figure: Extracted ion chromatogram (EIC) of compound.
Figure: Full range view of Compound spectra and potential adducts.




Figure 2.20: Second synthetic pathway of yielding compounds 41-43. 
Another approach was therefore explored (Figure 2.20), where 4-nitronaphthalene-1,8-
dicarboxylic anhydride could be firstly reduced into 69  as previously reported.277 4-
nitronaphthalene-1,8-dicarboxylic anhydride was added into ethanol. 20% palladium on carbon 
(Pd/C) was added into each solution while stirring. The reaction was allowed to stir at room 
temperature under a hydrogen atmosphere for 4 hours. Once the 4-nitronaphthalene-1,8-
dicarboxylic anhydride had dissolved in ethanol and had undergone a transfer into 69, the 
reaction became fluorescent under a UV torch. The solution was filtered through a celite plug. 
The solvent was removed in-vacuo to afford 69, with a yield of 82%. The 1H NMR of 
compound 69 is shown in Figure 2.21. As can be seen, the naphthalimide moiety is represented 
by signals at 8.7, 8.4, 8.2, 7.6 and 6.9 ppm, while the peak at 7.8 ppm indicated the presence 
of another NH2, further indicating successful completion of the reaction. The LCMS (Figure 
2.22) had also displayed purity of 69 following the reduction of 4-nitronaphthalene-1,8-
dicarboxylic anhydride.  
 
Scheme 2.11: Synthesis of 69. 






Figure 2.21:  The 1HNMR Spectrum of 69 (500 MHz, DMSO-d6, 298 K.) 
 
 
Figure 2.22:  LCMS Characterisation of 69: (a) Analytical HPLC trace of pure 69; Rt = 20.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 214.2 [M + H]+. (c) 
Mass Spectrum detected between Rt = 19.0-21.0 mins (157 scans); Calculated for [M + H]
+ = 214.2; 









66, 67 and 68 were dissolved in ethanol separately. Triethylamine was added into each reaction 
with appropriate quantities of 69. All three reactions were allowed to reflux at 85°C for 12 
hours respectively. The solvents in all three reactions were removed in-vacuo to afford white 
solids. The products were analysed by 1H NMR and LCMS and it was evident that the starting 
materials were returned in each case. Various solvents were used when repeating the reaction. 
However, in all cases the starting materials had not reacted to form the desired products. The 
free amine products were returned as the reaction had not proceeded further.  
 
Scheme 2.12: Syntheses of 70, 71 and 72. 
xii) Ethanol/Methanol/Toluene/Dimethylformamide/Dichloromethane/Chloroform/ 
Tetrahydrofuran, H2, Pd/C 
 
The third proposed synthetic pathway (Figure 2.23) was to firstly involve the mono-boc 
protection of the aliphatic linker, followed by the reaction with 4-nitronaphthalene-1,8-
dicarboxylic anhydride, which will be reduced into 4-aminonaphthalene-1,8-dicarboxylic 
anhydride, which will be deprotected with trifluoroacetic acid:dichloromethane (50:50) and the 






Figure 2.23: Third proposed synthetic pathway of compounds 41-43. 
 
51, 52 and 53 were dissolved in toluene with triethylamine before the addition of 4-
nitronaphthalene-1,8-dicarboxylic anhydride. All three reactions were allowed to reflux at 
85°C for 12 hours. The solvents in all three reactions were removed in-vacuo to afford crude 
white solids in all three reactions. All three crude products were purified via column 
chromatography to afford the products 73, 74 and 75 with yields of 90%, 83% and 80%, as 
previously reported by Guo et al.278 1H NMR confirmed the successful outcome of the reaction 
(See Appendix). 
 
Scheme 2.13: Syntheses of 73, 74 and 75. 
xiii) Toluene, triethylamine, 4-nitronaphthalene-1,8-dicarboxylic anhydride 
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The next step involved the reduction of the NO2 group. 73, 74 and 75 were all dissolved in 
ethanol before 20% of palladium on carbon (Pd/C) were added into all three reactions and the 
reactions were allowed to stir for 4, 6 and 12 hours under H2 atmosphere. Once the reactions 
had completed, the solutions were filtered through a plug of celite and the solvents were 
removed in-vacuo to afford yellow solids 76, 77 and 78, as reported by Andersen et. al.279 The 
yields for 76, 77 and 78 were 89%, 84% and 81% respectively. The 1H NMR of compound 77 
is shown in Figure 2.24. As can be seen, the naphthalimide moiety is represented by signals at 
8.6, 8.4, 8.2, 7.6 and 6.9 ppm, the N-H peak was visible at 6.7 ppm, the aliphatic peaks were 
visible on the 1H NMR spectrum at 4.3, 2.8, 1.59, 1.41 and 1.0 ppm, the boc-protecting group 
was visible at 1.39 ppm, while the peak at 7.4 ppm indicated the presence of NH2, further 
indicating successful completion of the reaction.  
 
Scheme 2.14: Syntheses of 72, 73 and 74. 
xiv) Ethanol, H2, Pd/C 
 
 
Figure 2.24:   The 1H NMR Spectrum of 77 (500 MHz, DMSO-d6, 298 K.) 
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76, 77 and 78 were each dissolved in dichloromethane and trifluoroacetic acid (50:50). All 
three reactions were allowed to stir at room temperature. The deprotection of 76 required 1 
hour to form the product 79. The reduction of 77 required 2 hours to form the product 80 and 
the reduction of 78 required 4 hours to form the product 81. The solvent was removed with N2 
and in-vacuo. The title compounds appeared as orange residues in all three cases and were used 
directly without further purification.  
 
Scheme 2.15:  Syntheses of 79, 80 and 81. 
xv) Dichloromethane, trifluoroacetic acid 
 
The final step in this proposed synthesis involved the reaction with diethyl squarate, 50. 
79, 80 and 81 were separately dissolved in ethanol before the addition of triethylamine. Once 
79, 80 and 81 had fully dissolved, 4-diethoxycyclobut-3-ene-1,2-dione was added into each 
reaction. After 12 hours, the solvent was removed from each reaction in-vacuo to afford yellow 
solids. The yellow solids were analysed by 1H NMR and LCMS analysis and it was evident 
that the starting materials were returned and the reactions had not formed the desired products. 
Various solvents were used in theses reactions. However, the starting materials were returned 
as the reaction had not proceeded in each case, as the free amine starting materials were 
returned. 
 





The fourth proposed synthetic pathway (Figure 2.25) entailed the mono-boc protection of the 
aliphatic linker, followed by the reaction with diethyl squarate to form the di-substituted 
derivative. This was followed by the deprotection and the final reaction with the 4-
bromonaphthalene-1,8-dicarboxylic anhydride. We envisaged that this bromo-derivative could 
be reacted with ammonia to yield the desired amino substituted products.  
 
Figure 2.25: Fourth proposed synthetic pathway of synthesising compounds 41-43. 
66, 67 and 68 were separately dissolved in ethanol before the addition of triethylamine in each 
reaction. 4-bromonaphthalene-1,8-dicarboxylic anhydride was added into each reaction until 
fully dissolved. All three reactions were allowed to reflux at 85°C for 12 hours, as previously 
reported by O’ Malley.280 The solvent from each reaction was removed in-vacuo to afford three 
crude products. All three crude products were purified via column chromatography to afford 
pure products, which appeared as yellow solids, with yields of 89%, 92% and 81%. The 1H 
NMR confirmed the purity of 85 as each signal corresponded to each proton. However, as 
previously observed, the spectra were significantly broadened (Figure 2.26). LCMS confirmed 




Scheme 2.17:  Syntheses of 85, 86 and 87. 
xvii) Ethanol, triethylamine, 4-bromonaphthalene-1,8-dicarboxylic anhydride 
 
Figure 2.26:  The 1H NMR Spectrum of 87 (500 MHz, DMSO-d6, 298 K.) 
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Figure 2.27:  LCMS Characterisation of 85: (a) Analytical HPLC trace of pure 85; Rt = 38.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 717.3 [M + H]+. (c) 
Mass Spectrum detected between Rt = 37.0-39.0 mins (157 scans); Calculated for [M + H]
+ = 717.3; 
Mass Found (ESI+) = 716.7 [M + H]+.  
 
The final step involved conversion of the bromo-naphthalimides to the amino-naphthalimides 
by reaction with ammonia. 85, 86 and 87 were dissolved in ethanol with 20% ammonia. All 
three reactions were allowed to reflux at 85°C for 12 hours. The solvents from each reaction 
were removed in-vacuo to afford yellow solids. Each solid was analysed and it was evident 
that the reactants were returned. Neat ammonia was also used as a solvent under more harsh 
reaction conditions to force conversion. However, in all cases, starting materials were returned 
according to 1H NMR and LCMS analysis. 
 









The fifth proposed synthetic pathway saw a slight variation of the design, whereby a butyl-
amine would be substituted at the 4-position of the naphthalimide. This entailed the mono-boc 
protection of the aliphatic linker, followed by the reaction with diethyl squarate to form the di-
substituted derivatives. This was followed by the deprotection and the final reaction with the 
4-bromonaphthalene-1,8-dicarboxylic anhydride. We envisaged that this could be reacted with 
n-butylamine to yield the desired products (Figure 2.28).  
85, 86 and 87 were dissolved in ethanol and 20% n-Butylamine was added into each reaction 
accordingly. All three reactions were allowed to reflux at 85°C for 12 hours. The solvents from 
each reaction were removed in-vacuo to afford yellow solids. Each solid was analysed by 1H 
NMR and LCMS and it was evident that the reactants were returned in each case. After all 
solvents have been used in this reaction, 85, 86 and 87 were dissolved in pure n-Butylamine. 
All three reactions were allowed to reflux at 85°C for 12 hours respectively. The solvent from 
each reaction was removed in-vacuo to afford yellow solids. Each product was analysed by 1H 
NMR and LCMS and that the starting materials were returned, as the reaction had not 
proceeded further.  
 
Scheme 2.19:  Syntheses of 94, 95 and 96. 
xix) Ethanol/Toluene/Dimethylformamide/Dichloromethane/Chloroform/ Tetrahydrofuran. 
Figure 2.28: Proposed synthetic pathway of yielding compounds 91-93. 
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The sixth explored option to attempt to synthesise the desired products was via Tin(II) chloride 
reduction of the previously discussed nitro-derivatives, which is a softer method of reduction 
(Figure 2.29). 47, 48 and 49 were dissolved in 10N hydrochloric acid, acetic acid before the 
addition of tin(II) chloride/iron. Ethanol and H2O were added into the reaction as solvents. The 
three reactions were allowed to reflux at 85°C for 12 hours. The solutions were filtered through 
a celite plug and the solvents were removed in-vacuo to afford orange solids. The solids were 
analysed by 1H NMR and LCMS and it was clear that the desired products had not formed in 
these reactions.  
Figure 2.29: Sixth synthetic pathway of compounds 41-43. 
 
 
Scheme 2.20:  Attempted syntheses of 41, 42 and 43.  
 
xx) Ethanol/Toluene/Dimethylformamide/Dichloromethane/Chloroform/ Tetrahydrofuran,   





The final proposed synthetic step attempted involved the synthesis of compounds 44-46, where 
the naphthalimide is substituted at the ‘tail’ (Figure 2.30). This synthetic pathway entailed the 
mono-boc protection of the aliphatic linker, followed by the reaction with diethyl squarate to 
form the di-substituted derivatives. This was followed by the deprotection and the final reaction 
with the 4-Bromo-N-n-butyl-1,8-naphthalimide to yield the desired products 44-46.  
 
Figure 2.30: Proposed synthetic pathway of compounds 44-46.   
 
66, 67 and 68 were dissolved in ethanol with H2O before the addition of triethylamine. 4-
bromo-N-n-butyl-1,8-naphthalimide were added into each reaction until dissolved. All three 
reactions were allowed to reflux at 85°C for 12 hours. The solvents were removed in-vacuo to 
afford a yellow solid. The solids were analysed by 1H NMR and LCMS analysis and suggested 
that starting materials were returned in each case as well as other side products that could not 
be identified. Both 1H NMR and LCMS did not show any evidence of successful compound 
formation (Figures 2.31 and 2.32), as this spectrum resembles the starting material. This 
suggested a mixture of starting materials and side products. 
 















2.2.8 Synthesis of 97 
In order to provide a comparison of compounds that either contain 1 or 2 naphthalimides with 
or without a squaramide, compound 97 and 98 as previously reported were also synthesised as 
model compounds, where the syntheses have followed the procedures previously conducted in 
order to obtain the desired products.281, 282 The spectroscopic data of both synthesised model 
compounds match the spectroscopic data obtained in the previous studies. The spectroscopic 
data of both synthesised model compounds match the spectroscopic data obtained in the 
previous studies.281, 282 
 
Scheme 2.22: Synthesis of 97. 
xxii) Ethanol, triethylamine, naphthalene-1,8-dicarboxylic anhydride  
 
The synthesis of 97 involved dissolving naphthalene-1,8-dicarboxylic anhydride in ethanol and 
triethylamine, followed by an addition of 1,8-octanediamine. The reaction was allowed to 
reflux at 85°C for 12 hours. The solvent was removed in-vacuo to afford the crude product. 
The desired product was purified via column chromatography to afford a white solid, which 
was the pure product with a yield of 84%. The final compound was made according to the 1H 
NMR (Figure 2.33), where the naphthalimide region peaks were represented by the peaks at 
8.49, 7.71 and 7.68 ppm. The aliphatic region was represented by the peaks at 4.22, 2.08 and 
1.34 ppm. The process of aggregation was evident, when the 1H NMR at 358 K had indicated 
clearer proton signals (Figure 2.34). The process of aggregation was also evident in the 
solubility issues which prevented the possibility of collection of reliable 13C NMR spectrum. 
The presence of the compound was also confirmed by the HR-MS (Figure 2.35).  
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Figure 2.33:  The 1H NMR Spectrum of 97 (500 MHz, DMSO-d6, 298 K.) 
 
 







Figure 2.35:  HRMS spectrum of 97. 
 
 
2.2.9 Synthesis of 98 
 
Scheme 2.23:  Synthesis of 98. 
xxiii) Ethanol, triethylamine, 1-aminobutane  
 
The synthesis of 98 involved dissolving naphthalene-1,8-dicarboxylic anhydride in ethanol and 
triethylamine, followed by the addition of 1-aminobutane. The reaction was allowed to reflux 
at 85°C for 12 hours. The solvent was removed in-vacuo to afford the crude product. The 
desired product was purified via column chromatography to afford a white solid, which was 
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the pure product with a yield of 81%. 1H NMR confirmed the purity of 98 (Figure 2.36), where 
the proton signals at 8.40 and 7.8 ppm both represented the protons in the naphthalimide 
moiety. The aliphatic region protons were represented by the signals at 4.0, 1.5, 1.3 and 0.9 
ppm. The purity of the compound 98 was also confirmed by the LCMS analysis (Figure 2.37).   
 
Figure 2.36:  The 1H NMR Spectrum of 98 (500 MHz, DMSO-d6, 298 K.)  
 
Figure 2.37:  LCMS Characterisation of 98: (a) Analytical HPLC trace of purified 98; Rt = 42.0 mins 
(0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 254. [M + H]+. (c) 
Mass Spectrum detected between Rt = 42.0-43.5 mins (157 scans); Calculated for [M + H]
+ = 254.3; 











In conclusion, we have successfully synthesised a family of compounds 38-40, 47-49, 97 & 98 
based on the squaramide-naphthalimide moiety, where the new compounds were characterised 
by various techniques including: 1H NMR, 13C NMR, high resolution mass spectrometry and 
infrared spectroscopy.   
Different synthetic pathways have been explored to synthesise the desired target compounds. 
The initial pathway when synthesising 1,8-naphthalimides with different aliphatic chain 
lengths have been explored. However, when diethyl squarate was added in the further steps, 
the reactions had only worked partially, where one side of the diethyl squarate had reacted to 
form 1,8-naphthalimide bound to the mono-squaramide. This occurred with the naphthalimides 
of different aliphatic chain lengths: 2-carbons, 5-carbons and 8-carbons. It was concluded that 
only one side of diethyl squarate had reacted to form a mono-naphthalimide, which precipitated 
immediately out of the reaction and the lack of solubility of mono-naphthalimide prevented the 
reaction proceeding further.    
Another approach that was explored to synthesise the final desired compounds was reacting: 
diethyl squarates with mono-boc protected amines with the lengths of 2-carbons, 5-carbons 
and 8-carbons aliphatic chains. These reactions had formed the desired mono-boc protected 
squaramides with aliphatic chains of three different lengths. These squaramides were 
deprotected and reacted with 1,8-naphthalic anhydride respectively to form the desired final 
products, which were purified via centrifuging in ethanol and diethyl ether to afford the yellow 
solids. The key findings in this approach had also highlighted the stronger reactivity of the di-
substituted derivatives, where the desired products were made using this method, compared to 
the first attempt.  
 
The exact same approach was used with 4-nitro naphthalic anhydride to synthesise the desired 
products with a 4-nitro moiety on the 4-carbon position of the naphthalimide. Multiple attempts 
were made to synthesise 4-amino bis-naphthalimides as our desired compounds. It was first 
attempted to reduce 4-nitro bis-naphthalimides with palladium on carbon under a hydrogen 
atmosphere. Due to this reaction not being successful, due to the lack of solubility of 4-nitro 
bis-naphthalimides, we have changed the approach to first reduce the commercially available 
4-nitro naphthalic anhydride to 4-amino naphthalic anhydride, where the 1H NMR and LCMS 
data highlighted the formation and the purity of the 4-amino naphthalic anhydride made. The 
deprotected squaramides that were previously made were reacted with 4-amino naphthalic 
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anhydride. Solubility issues were the main factor preventing this reaction from proceeding 
further. It was only possible to dissolve 4-amino naphthalic anhydride in dimethylformamide. 
However, when the squaramide was added into the reaction, the reaction did not proceed any 
further, which indicated no reactivity, even with 10 equivalent excess of 4-amino naphthalic 
anhydride. This was also supported by the 1H NMR and LCMS, where the starting materials 
were returned, which further concluded their low solubility. 
 
Another approach that was explored was reacting the mono-boc protected amines with three 
different aliphatic chain lengths with commercially available 4-nitro naphthalic anhydrides to 
synthesise 4-nitro naphthalimides. The 4-nitro naphthalimides were purified via column 
chromatography. These 4-nitro naphthalimides were reduced with palladium on carbon under 
hydrogen atmosphere into 4-amino naphthalimides, once the reactions had undergone 
completion. The newly formed 4-amino naphthalimides were then deprotected and reacted with 
diethyl squarate in all three cases. However, this reaction was not successful, due to no 
reactivity of diethyl squarate in this reaction, which was supported by 1H NMR and LCMS. 
Another approach we tried was reacting the commercially available 4-bromo naphthalic 
anhydride with the three different deprotected squaramides. The reactions were successful and 
the three desired 4-bromo squaramide-naphthalimide conjugates were synthesised. The 4-
bromo squaramide-naphthalimide conjugates were purified via column chromatography. 
Various attempts have been made to aminate this family of compounds into the desired 
products via the addition of ammonia and even as a last resort using ammonia as the solvent. 
The starting materials were returned and the desired compounds were not made, due to the low 
reactivity of 4-bromo squaramide-naphthalimide conjugates. Another approach that was 
explored involved using the previously synthesised 4-bromo squaramide-naphthalimide 
conjugates and reacting them with n-butylamine in different solvents. This was not successful 
and the last attempt was using n-butylamine as a solvent and the reaction had failed to undergo 
completion to synthesise the desired compounds. This further proved that 4-bromo squaramide-
naphthalimide conjugates had no reactivity. 
 
Another approach we tried was reacting the 4-nitro squaramide-naphthalimide conjugates with 
Tin (II) Chloride, hydrochloric acid, water and acetic acid. This was also unsuccessful and the 
starting materials were returned as analysed, due to no solubility. The last resort explored, 
involved reacting 4-Bromo-N-n-butyl-1,8-naphthalimide with 66, 67 and 68 in different 
solvents. The starting materials were not reactive and the desired products were not obtained.  
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As a result, we have synthesised a bis-naphthalimide without a squaramide moiety which 
involved using 1,8-naphthalic anhydride and reacting it with 1,8-diaminooctane. This reaction 
was successful and the crude product was obtained. The crude product obtained was purified 
via column chromatography. We have also synthesised a mono-naphthalimide via reacting n-
butylamine with 1,8-naphthalic anhydride. This reaction was also successful and it generated 
the desired crude product. The crude product was purified via column chromatography to 
obtain the pure desired product. Both the desired compounds and their syntheses had to be 
altered in this chapter due to reduced reactivity of starting materials and solubility issues.   
 
Although the syntheses of these products were very challenging, we were successfully able to 
form 6 novel squaramide-containing bis-naphthalimides and 2 model naphthalimide 
compounds. During their syntheses, several interesting experimental observations led us to 
conclude that self-aggregation in solution appears to be a significant factor in the behaviour of 
this family of compounds in solution. The properties of these novel compounds will be 





























Chapter 3 Self-Assembly properties of the novel compounds  
3.1 Introduction  
In recent years, 4-substituted-1,8-naphthalimide derivatives have increased scientific interest 
due to their potential use as polymerizable fluorophores for synthetic polymers.283 Various 
different naphthalimide derivatives have been synthesised recently due to their potential uses 
as DNA binders but also due to their self-assembly properties.284 Similarly, squaramide based 
compounds are known for their self-assembly and molecular recognition properties.240 In the 
previous chapter, we discussed the synthesis of several squaramide-naphthalimide conjugates. 
Precipitation of these compounds was common, due to the novel squaramide-naphthalimide 
conjugates undergoing self-aggregation, as previously observed with similar analogues.266 It 
was also concluded that this resulted in their low reactivity in a number of reactions and their 
low solubility in nonpolar solvents. Although, significant difficulty was encountered in the 
synthesis of this family of compounds, 6 novel compounds 38-40, 47-49, and 2 model 
compounds 97, 98 were successfully reported. During the characterisation of compounds 38-
40, we observed significant broadening of the 1H NMR spectra and this led us to suspect some 
level of compound self-assembly was occurring in solution. Thus, as part of this chapter, we 
will investigate this behaviour using a series of spectroscopic techniques such as temperature 
dependent NMR, UV/Vis and fluorescence time studies, UV/Vis and fluorescence 
concentration studies as well as scanning electron microscopy (SEM). 
 
3.2 Variable temperature studies 
Prior to performing variable temperature experiments in the appropriate solvent, the optimised 
temperature range for VT-NMR studies was determined. DMSO-d6 was chosen for these tests, 
due to its high boiling point. 1H NMR spectra were collected every 10 minutes with 10 K 
temperature intervals ranging from 298 K to 358 K (Figure 3.1). At low temperature of 298 K, 
the NMR appears broad and it is very challenging to depict and assign each signal to the 
corresponding proton on the chemical structure. However, when the temperature was raised to 
at least 328 K, the corresponding proton peaks had cleared up significantly and it started 
becoming easier to assign each corresponding proton of 38. When the temperature probe had 
reached its highest point of 358 K, each proton appeared very clear on the NMR spectrum and 
it was evident that the target compound 38 was made. The proton resonances that were 
broadened by the self-assembly process included the signals at 8.4, 8.5, 7.7 ppm in the 
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naphthalimide moiety, 7.4 ppm representing the N-H, 3.7 and 4.2 ppm representing both CH2s 
in the aliphatic region, where these signals had a much improved resolution when 1H NMR 
was taken at 358 K. This had indicated that these compounds underwent de-stacking when the 
temperature of the 1H NMR was increased, which was consistent with the previous findings 
observed with similar compounds.266 Moreover, when the sample was returned to 298 K, the 
spectrum was observed to undergo broadening again. These results are a clear indication that 
this compound had undergone the process of self-assembly. See Figures 3.2 and 3.3 for a direct 
comparison in the case of compound 38. Similar 1H NMR experiments were performed for the 
remaining bis-naphthalimides at 298 K and 358 K. The spectra showed significant broadening 
in each case and seemed to be unaffected by linker length. As an example, see Figures 3.4 and 





Figure 3.1:  Variable temperature 1H NMR (500 MHz, DMSO-d6) of 38. Room temperature: 298 
K (blue), 308 K (red), 318 K (teal), 328 K (violet), 338 K (yellow), 348 K (orange), 358 K (light green), 









Figure 3.2:  1H NMR (500 MHz, DMSO-d6) of 38 at 298 K. 
 
 









Figure 3.4:  1H NMR (500 MHz, DMSO-d6) of 39 at 298 K. 
 
 







3.3 UV-Vis and Fluorescence time studies 
All of the above data indicates the process of self-assembly taking place, where the novel 
squaramide-naphthalimide conjugates undergo stacking or intermolecular H-bonding in 
solution. To confirm the results of the 1H NMR experiments, UV-Vis dilution studies were also 
conducted and will be further discussed in the following section. UV-Vis dilution will be 
closely analysed and discussed according to the Beer-Lamber Law285 (Figure 3.6). The 
compounds have demonstrated that they do not obey the Beer-Lambert Law, where there is no 
linear relationship between the concentration and the absorbance of the solutions of each 
compound in DMSO (Table 3.1), which further demonstrated the process of self-assembly 
taking place. UV-Vis data was recorded using a Varian Cary 50 UV-Vis Spectrophotometer at 
25°C with the initial concentration of each compound at 100μM and the final concentration of 
each compound at 20μM after a total of 6 serial dilutions. The absorbance was recorded from 
200 nm to 900 nm. 
   





















(M-1cm-1) at (295 
nm± 15 nm) 
Molar Extinction 
Coefficient  
(M-1cm-1) at (335 
nm± 15 nm) 
38 3 100x10-6 13.1x10-6 0.999 0.999 3661.8 2639.9 
39 3 100x10-6 13.1x10-6 0.999 0.999 3502.7 2529.6 
40 3 100x10-6 13.1x10-6 0.999 1.000 4476.9 1063.9 
47 3 100x10-6 13.1x10-6 1 / 1709.7 / 
48 3 100x10-6 13.1x10-6 0.997 / 3638.3 / 
49 3 100x10-6 13.1x10-6 0.996 / 4568.9 / 
97 3 100x10-6 13.1x10-6 0.996 / 3280.7 / 
98 3 100x10-6 13.1x10-6 0.997 / 1525.2 / 




Figure 3.7:  UV-Vis absorbance time study of 38 over the course of 12 hours in DMSO. 
 
Figure 3.8:  UV-Vis absorbance time study of 97 over the course of 12 hours in DMSO. 
 
UV-Vis time studies of 38-40, 47-49, 97 and 98 were carried out in DMSO. 38-40 UV-Vis 
spectra time studies showed a dramatic decrease in UV absorbance over time. This indicates 
that due to the presence of a squaramide moiety in unsubstituted bis-naphthalimides, the 
squaramide may be responsible for these aggregation processes. The UV-Vis absorbance of 38 
is shown in Figure 3.7 and had dropped significantly at its λmax of 345 nm over the course of 
38 




12 hours as indicated. Although 39 had also dropped in UV absorbance at its λmax of 345  nm 
over the course of 12 hours, the percentage decrease in absorbance was 45% less than seen 
with 38 (See Appendix). The UV absorbance percentage decrease of 40 at its λmax of 345 nm 
was approximately 80% less than seen with 38. These results can conclude that the further the 
squaramide moiety is from the naphthalimide moiety, the process of self-aggregation is less 
significant. Aggregation would be expected to result in a decrease in absorbance, due to their 
decreased solubility as observed with other similar derivatives.266, 286 It was evident that 47-49 
all had a λmax of 350 nm but with no decrease in absorbance in the time study. It was also 
observed that 97 and 98 had a λmax of 350 nm (See Appendix), where these compounds did not 
undergo decrease in UV-Vis absorbance over time, and this suggests that the self-assembly 
was not occurring for compounds 47-49, 97 and 98. See Figure 3.8 for the corresponding 
spectrum for compound 97 which does not contain a squaramide. 
In contrast to the UV/Vis time studies, the fluorescence time studies did not indicate any 
changes in fluorescence intensity over time at 25°C. The characteristic fluorescence for 
naphthalimides is at 445 nm, where the fluorescence time study of 38 is shown (Figure 3.9). 
Even though there were large changes in UV-Vis time studies, these were not mirrored in the 
fluorescence studies. This suggested that fluorescence was not able to observe the self-
assembly formation of the final compounds due to their weak fluorescence. Furthermore, in 
bis-naphthalimides containing a squaramide moiety, this self-assembly behaviour is not 
observed via their fluorescence. This can be described by the squaramide possibly quenching 
the fluorescence of the naphthalimide moiety. Concentration dependent studies were suggested 
to observe the expected decrease in both UV-Vis absorbance and fluorescence with the 







Figure 3.9:  Fluorescence intensity (au) time study of 38, with an excitation wavelength at 440 
nm over the course of 12 hours in DMSO. 
 
3.4  Extinction coefficient studies 
Figure 3.10:  UV-Vis Absorbance of 2.6 mg of 38 and its absorbance at 345 nm vs the concentration 





The extinction coefficients were taken immediately after dissolving each compound in DMSO. 
The UV-Vis concentration study had revealed that with decreasing concentration, each 
compound had decreased in terms of their UV light absorbance. This decrease was exponential 
for all compounds. This exponential decrease was observed from the molar extinction 
coefficient study starting from a 100x10-6 M concentration of each compound in DMSO with 
14.5x10-6 M decrease of concentration for each run for a total of 6 runs, with the final 
concentration being 13.1x10-6 M. The exponential decrease was observed at the highest UV-
Vis absorbance wavelength for each compound, as it differed in each case. The exact same 
concentrations of 100x10-6 M for each compound were tested under the fluorescence 
spectrometer to see the same decrease in terms of their light emittance. Each compound 
concentration was again reduced by 14.5x10-6 M for a total of 6 times from the initial 100x10-
6 M concentration, with the final concentration being 13.1x10-6 M as tested previously with UV 
light absorbance experiments. The same effect of decrease of fluorescence was observed for 
all compounds. However, both the decrease in intensity and the decrease in concentration at 
the highest wavelengths for all compounds emitting light (435-440 nm) was exponential. This 
concludes that both the UV light absorbance and fluorescence of these compounds are 
concentration dependent. These compounds had a stronger UV light absorbance and emittance 
of light with higher concentrations and weaker UV light absorbance and emittance of light in 
lower concentrations. 
Figure 3.11:  UV-Vis Absorbance of 5.2 mg of 38 and its absorbance at 345 nm vs the 
concentration (M) of 38 in DMSO. 
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3.5 Scanning electron microscopy studies 
Having observed the aggregation in these compounds in the UV-Vis and the proton VT-NMR 
studies, we have also decided to observe this process in the solid state using Scanning Electron 
Microscopy. 
The morphological features of 38-40, 97 and 98 in both DMSO and DMSO:water (50:50) was 
measured upon dropcasting the samples onto silica support using 1 µM stock solutions of each 
structure. The samples were allowed to dry in air and under vacuum prior to imaging.  
 
In DMSO, all compounds demonstrated the formation of compact films. 38 appears to form 
quite complex structures in Figure 3.12. Compound 39 also showed the formation of complex 
structures in Figure 3.13. This further supports the fact that these compounds are undergoing 
self-assembly in DMSO due to aggregation of naphthalimide and squaramide moieties. 
However, more fibrillar networks were particularly visible in the case of 97 in Figure 3.14, 
where only the naphthalimide moieties underwent self-aggregation, while no fibrillar networks 
were visible in 98 due to no self-assembly taking place (See Appendix). When the experiments 
were repeated in DMSO:water (50:50), there was an element of formation of fibrillar fine 
structure forming in each case, suggesting that upon the addition of water, self-assembly was 
still seen to occur. This will be an important factor in the proceeding sections that will discuss 




Figure 3.12:  Scanning electron microscopy (SEM) images of compound 38 spotted with Au in 
DMSO, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 6000. 
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Figure 3.13:  Scanning electron microscopy (SEM) images of compound 39 spotted with Au in 
DMSO, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 6000. 
 
Figure 3.14:  Scanning electron microscopy (SEM) images of compound 97 spotted with Au in 
DMSO, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 6000. 
 
38-40 and 97 have displayed processes of aggregation, as these compounds underwent π-
π stacking interactions, which involved the naphthalimide moiety due to its aromatic nature 
and the squaramide aromatic moiety also being involved in π-π stacking in compounds 38-40. 
It was evident that 38-40 formed quite complex structures, which appeared as sponge like 
structures when zoomed in under a high magnification in pure DMSO. 98 had appeared as 
fibrillar structures, which did not display the process of self-assembly taking place. The SEM 
study was repeated in DMSO:water (50:50) solution.  
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Figure 3.15:  Scanning electron microscopy (SEM) images of compound 38 spotted with Au in 
DMSO:H2O 50:50, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 
6000. 
 
Figure 3.16:  Scanning electron microscopy (SEM) images of compound 39 spotted with Au in 




Figure 3.17:  Scanning electron microscopy (SEM) images of compound 97 spotted with Au in 
DMSO:H2O 50:50, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 
6000.  
38-40 have formed similar complex structures in DMSO:Water, (50:50) which highlighted the 
process of self-aggregation of both squaramide and naphthalimide moieties also taking place 
in this solvent combination. 97 had formed similar fibrillar structures in DMSO:Water (50:50), 
which indicated that these compounds had undergone π-π stacking interactions in the 
naphthalimide moieties, without the presence of the squaramide. It was also reported that 38-
40 formed nanofilaments, which appeared as sponge like structures and 97 (Figure 3.17) had 
formed fibrillar structures in DMSO:water (50:50) when zoomed in under a high 
magnification. We have attempted to grow crystals from DMSO solution for the novel 
synthesised compounds. However, the novel compounds had formed amorphous solids, as they 
did not crystallise. 
3.6 Conclusion 
In this chapter, we described the processes of self-assembly of the novel bis-naphthalimides 
using techniques such as: Variable Temperature 1H NMR, UV-Vis Absorption Spectroscopy, 
Fluorescence Spectroscopy and Scanning Electron Microscopy. These processes had further 
concluded that self-aggregation of the novel synthesised bis-naphthalimides had taken place. 
Variable temperature 1H NMR have revealed the process of self-aggregation of all synthesised 
bis-naphthalimides. Increased temperatures caused the broad spectra of the synthesised bis-
naphthalimides to become better resolved in sharper proton signals, enabling us to observe 
disaggregation with increasing temperatures. It is possible to characterise all 1H signals at a 
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higher temperature spectrum, especially at 358 K in all synthesised bis-naphthalimides. The 
signals representing the naphthalimide moiety protons have also become more resolved with 
the increased temperature. The N-H signals in the squaramide moiety in all synthesised bis-
naphthalimides containing this moiety were not well resolved at 293 K. However, as the 
temperature was increased to 358 K in all cases, the signal representing the N-H of the 
squaramide moiety had become much sharper and more intense, enabling us to fully 
characterise the squaramide containing bis-naphthalimides. When the 1H NMR was taken at 
298 K following these variable temperature spectra, the spectra collected had broadened again, 
indicating self-assembly of these novel bis-naphthalimides taking place. 
38-40,  47-49, 97 and 98 were all examined using UV/Vis spectroscopy and fluorescence 
emission spectrometry. 38-40, which were the unsubstituted bis-naphthalimides had shown a 
significant decrease in UV light absorbance over the time of 12 hours. This also indicates a 
process of self-assembly taking place.   
 
Scanning Electron Microscopy (SEM) was used to analyse the morphological features of these 
compounds. SEM was performed both in pure DMSO and DMSO:H2O (50:50) solution. In 
summary, SEM analyses have revealed the presence of self-assembly interaction of all the 
synthesised bis-naphthalimides. 38-40 and 97 have shown significant processes of aggregation. 
38-40 planar compounds have all underwent π-π stacking interactions, which involved both the 
squaramide and naphthalimide moieties due to their aromatic nature at a room temperature. 97 
had also formed fibrillar structures, due to π-π stacking interactions taking place only in the 
naphthalimide moieties, as no squaramide moiety was present. 38-40 and 97 formed 
nanofilaments when zoomed in under a high magnification, which showed sponge like 
structures when zoomed out on the SEM. Although, the exact mechanism of self-assembly 
undergoing molecular interaction giving these compounds their morphology is not clear, it is 
evident that high degree of aggregation is taking place that appears to be organised to give rise 
to such patterns. 97 was another novel bis-naphthalimide compound synthesised, without the 
squaramide moiety and it was also examined under the SEM, along with a previously 
synthesised mono-naphthalimide. Compound 97 had formed nano fibres in high density also 
indicating self-assembly taking place. No fibres or nanofilaments in high density were visible 
for 98, which indicated no self-assembly taking place, as the compound was not a bis-
naphthalimide and it did not contain a squaramide moiety. The properties of 38-40, 47-49, 97 
and 98 binding to DNA are examined in the following chapter to observe whether these 
compounds can bind to DNA, while undergoing the process of self-assembly. 
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Chapter 4 DNA binding studies 
4.1 Introduction  
In the previous sections of this thesis, squaramide containing bis-1,8-naphthalimide derivatives 
38-40, 47-49, bis-1,8-naphthalimide without squaramide moiety 97 and a mono-naphthalimide 
98 (Figure 4.1) were designed and synthesised and an evaluation of their self-assembly 
behaviour was undertaken. Overall, it was anticipated that possible noncovalent binding 
interactions of these compounds may allow binding to DNA via various interactions including 
intercalation, groove-binding (major and minor) and H-bonding to the negatively charged sugar 
phosphate backbone.287 Synthesising these planar structures was a necessary feature for the 
likelihood of intercalation, while keeping a squaramide moiety aiding the H-bonding 
interactions with DNA. Squaramide containing bis-1,8-naphthalimides were chosen because 
of the naphthalimides having DNA bis-intercalating properties, while their squaramide 
moieties have the ability to bind to DNA via H-bonding interactions (Figure 4.2). Compounds 
97 and 98 were synthesised as control compounds, where 97 was a bis-naphthalimide without 
a squaramide moiety, where it was compared to compounds 38-40, 47-49. Compound 98 was 
a mono-naphthalimide, which was compared to 38-40, 47-49 and 97, which were all bis-
naphthalimides. The final two compounds were compared to the model squaramide containing 
bis-naphthalimides 38-40, 47-49.   
 
 
Figure 4.1: Structures of the squaramide containing bis-1,8-naphthalimides 38-40, 47-49, bis-1,8-
naphthalimide without squaramide moiety 97 and a mono-1,8-naphthalimide 98. 
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In Chapter 3, the photophysical properties of these molecules in DMSO were investigated, 
along with their self-assembly properties via UV-Vis, Fluorescence studies and Scanning 
Electron Microscopy. In this chapter, their ability to bind to DNA in buffered aqueous solutions 
will be explored via UV-Vis absorbance and Fluorescence emission DNA interaction studies, 
along with Ethidium Bromide assays.  
 
Figure 4.2: Rationale in the design of 38-40, 47-49, 97 and 98 as DNA binding agents, and 
schematic of methods of binding to DNA helix. 
 
As a means of evaluating the DNA-binding affinity of 38-40, 47-49, 97 and 98, the following 
methods were chosen. Firstly, UV-Vis and fluorescence titration studies were used to 
determine whether there was any interaction between these synthesised compounds and DNA. 
Taking advantage of the inherent photophysical properties of the 1,8-naphthalimide 
fluorophore, Ethidium Bromide displacement assays were also carried out in order to have a 
comparative method that should provide complimentary evidence of DNA binding, after both 
UV-Vis absorbance and fluorescence emission tests were performed.   
 
4.2  UV-Vis DNA titrations 
As shown in Chapter 3, the naphthalimide conjugates of 38-40, 47-49, 97 and 98 absorb in the 
350-500 nm region of the electromagnetic spectrum. The nucleobases of DNA absorb at cca. 
250-260 nm. Therefore, any changes in the absorbance spectra of these molecules upon 
interacting with DNA can be easily followed. The possible noncovalent binding interactions of 
the synthesised compound  when binding to DNA include intercalation, groove-binding (major 
and minor) and H-bonding to the negatively charged backbone.   
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These changes could involve a shift in the wavelength of maximum absorbance (hypsochromic 
or bathochromic shifts) and most importantly a decrease in the absorption intensity 
(hypochromism). Any decrease of maximum absorbance after the introduction of DNA would 
indicate our target compounds binding with DNA. 
 
 
Figure 4.3: UV-Vis absorbance of 38, with DNA concentration increases of (0.00005 mg/mL) for 
a total of 25 runs with DNA. 
 
The UV-Vis absorbance of 38-40 was measured with different concentrations of DNA in PBS 
and it was evident that there was decrease of ~90% of UV absorbance of 38 (Figure 4.3) with 
increased DNA concentrations. This had corresponded to the possibility of 38 binding to DNA. 
Smaller decrease of ~40% in UV absorbance was observed for compound 39 and even a smaller 
decrease of ~25% in UV absorbance was observed for compound 40 with the same increased 
DNA concentrations (See Appendix). Control experiments have been done after 12 hours with 
each compound to observe different behaviour in binding to DNA and no change was observed. 
The control experiments could unfortunately not be done in PBS due to all compounds not 







Figure 4.4: UV-Vis absorbance of 47, with DNA concentration increases of (0.00005 mg/mL) for 
a total of 25 runs with DNA. 
 
The UV-Vis absorbance of compounds 47-49 was measured with different concentrations of 
DNA in PBS and it was visible that there was a only a very small decrease in UV absorbance 
of 47 (Figure 4.4) with increased DNA concentrations. However, very small decreases in UV-
Vis absorbance were also evident for compounds 48 and 49 with the same increased DNA 





Figure 4.5: UV-Vis absorbance of 97, with DNA concentration increases of (0.00005 mg/mL) for 
a total of 25 runs with DNA. 
 
 
Figure 4.6: UV-Vis absorbance of 98, with DNA concentration increases of (0.00005 mg/mL) for 





The UV-Vis absorbance had also slightly decreased for compounds 97 and 98 with increased 
DNA concentrations. Both compounds did not contain a squaramide moiety. This also 
indicated that weak DNA interaction was taking place for these compounds.  
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To further investigate, UV-Vis titration control experiments were also conducted, in which 
buffer was added instead of DNA. It was expected that no changes would occur in this case. 
However, due to the propensity of the molecules to self-assemble in solution, we wished to 
ensure that the observed changes were due to DNA binding and not self-assembly. However, 
this time PBS was added instead of DNA, where 0.5 μL equivalents of PBS were added into 
the solution each time, as the overall volume of the cuvette did not lead to dilution effects. 
Similarly the exact UV-Vis absorbance experiments were again conducted for 39 and 40.  
 
Figure 4.7: UV-Vis absorbance of 38, with PBS equivalents of DNA concentration increases of 
(0.00005 mL) for a total of 25 runs with PBS. 
 
Unfortunately, as can be seen with Figure 4.7, the absorbance spectrum of compound 38 tend 
to decrease and with the addition of PBS and the absence of DNA. The results have mirrored 
mostly the results of the same experiment conducted with DNA addition (Figure 4.3). The UV 
absorbance had also identically decreased with the equivalent PBS instead of DNA and 
mirrored the DNA equivalent addition. These results suggest that the observed changes may 
not be due DNA binding but to self-assembly or a combination of both. Thus these experiments 
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Figure 4.8: UV-Vis absorbance of 47, with PBS equivalents of DNA concentration increases of 
(0.00005 mL) for a total of 25 runs with PBS. 
 
The absorbance spectrum of compound 47 (Figure 4.8) had decreased only slightly and 
underwent significant hypochromism with the addition of PBS and the absence of DNA. The 
results have mirrored mostly the results of the same experiment conducted with DNA addition 
(Figure 4.4). The UV absorbance had also identically decreased with the equivalent PBS 
instead of DNA and mirrored the DNA equivalent addition, which indicated that very limited 




Figure 4.9: UV-Vis absorbance of 97, with PBS equivalents of DNA concentration increases of 
(0.00005 mL) for a total of 25 runs with PBS. 
 
Figure 4.10: UV-Vis absorbance of 98, with PBS equivalents of DNA concentration increases of 






Similar results were also observed for compounds 39 and 40, where the DNA titration 
experiments, and PBS control experiments did not differ (See Appendix). The DNA UV-Vis 
titration studies in which DNA concentration was increased in the presence of 38-40 were 
conducted.  The dramatic decrease in UV-Vis absorbance at cca. 350 nm, in response to DNA 
concentration increase. Interestingly, a trend appeared to show the greatest decrease of 
compound 38, with the smallest changes occurring in compound 40 (see figure 4.3 and 
Appendix).  This indicates, that although DNA was introduced into the compound in PBS, the 
drop in UV-Vis absorbance exactly mirrored the drop in UV-Vis absorbance when PBS 
equivalent was introduced in the test. Almost identical decreases of UV-Vis absorbance for 
compounds 39 and 40 were also observed with both DNA additions and PBS equivalent 
additions. For compounds 97 and 98, a drop in UV absorbance had also very closely resembled 
the DNA additions when PBS equivalents were added. These results suggested that the data 
from UV-Vis titrations may not be reliable in probing DNA binding ability and as such further 
investigation was required. In the next section, the fluorescence emission titrations will be 
discussed in which DNA concentration was increased in the presence of 38-40, 97 and 98. 
 
 
4.3 Fluorescence emission studies in presence of DNA  
The emission spectra of 38-40, 47-49, 97 and 98 (10 µM, 10 mM phosphate buffer, pH 7.4) 
were taken in the absence and presence of DNA (P/D = 0-25) upon excitation at 350 nm. The 
fluorescence emission studies were carried out to observe whether the synthesised compounds 
bound to DNA upon introduction. In contrast to the UV-Vis absorbance drop after the 
introduction of both DNA and PBS equivalents, it was expected that the fluorescence intensity 
of the synthesised compounds would undergo an increase in intensity, also indicating the 
process of intercalation taking place of the naphthalimide moieties of the synthesised 
compounds. Compounds 47-49 showed no fluorescence with and without the presence of DNA 
due to its electron withdrawing group being present on the naphthalimide moiety thus this 








Figure 4.11: Fluorescence intensity of 38, with an excitation wavelength at 400 nm, with an 
increased DNA concentration of (0.00005 mL) for a total of 25 runs in PBS. 
 
The fluorescence emission spectrum of compound 38 (Figure 4.11) had decreased only slightly 
with the addition of identical DNA concentration used in the UV absorbance tests. The results 
for 39 and 40 had also shown this decrease, indicating minimal DNA binding (See Appendix).  
 
 
Figure 4.12: Fluorescence intensity of 97, with an excitation wavelength at 460 nm, with an 
increased DNA concentration of (0.00005 mL) for a total of 25 runs in PBS. 
 101 
 
Figure 4.13: Fluorescence intensity of 98, with an excitation wavelength at 450 nm, with an 
increased DNA concentration of (0.00005 mL) for a total of 25 runs in PBS. 
 
The fluorescence emission spectrum of control compounds 97 (Figure 4.12) and 98 (Figure 
4.13) had a much more significant decrease in fluorescence emission with the addition of 
identical DNA concentration used in the UV absorbance tests; a clear indication that DNA 
binding may be occurring for these compounds. Further control experiments were conducted, 
where again the PBS equivalents of DNA concentrations were added and the fluorescence 
















Figure 4.14: Fluorescence intensity of 38 with an excitation wavelength at 400 nm, with PBS 
equivalents of DNA concentration increases of (0.00005 mL) for a total of 25 runs with 
PBS.  
 
Unfortunately, as can be seen with Figure 4.14, the emission spectrum of compound 38 was 
shown to decrease with the addition of PBS and the absence of DNA. The results have mirrored 
mostly the results of the same experiment conducted with DNA addition (Figure 4.11). The 
UV absorbance had also identically decreased with the equivalent PBS instead of DNA and 
mirrored the DNA equivalent addition, which indicated that very limited DNA binding was 







Figure 4.15: Fluorescence intensity of 97 with an excitation wavelength at 450 nm, with PBS 




Figure 4.16: Fluorescence intensity of 98, with an excitation wavelength at 400 nm with PBS 




Both 97 and 98 had displayed a more significant drop of fluorescence compared to 38, 39 and 
40. However, the decrease in fluorescence for PBS equivalent increase was identical to the 
DNA concentration increase. This had indicated that these tests were not sufficient enough to 
note any binding to DNA. It was therefore concluded that Ethidium Bromide displacement 
measurements should be conducted as an alternative method to measure DNA binding.  
 
The emission spectra of 38 (10 µM, 10 mM phosphate buffer, pH 7.4) in the absence and 
presence of DNA were shown in Figure 4.19 and Figure 4.24 respectively. When 38-40, 97 
and 98 were excited at 345 nm and upon the titration with DNA, the emission spectra displayed 
almost an identical decrease in both fluorescence intensity and UV absorbance for PBS 
equivalents in all compounds tested. Taken together the results of these experiments are  largely 
inconclusive, where the observed changes may be a result of either DNA binding or self-
assembly or a combination of both processes occurring in solution. The decrease of 
fluorescence intensity with and without DNA introduction for all synthesised compounds was 
not greater than 30% in all cases and this may indicate that even if DNA binding is occurring, 
it is not happening to a large extent.   
 
4.4 Displacement Assays using Ethidium Bromide  
In a final attempt to determine reliably whether DNA binding was occurring or not, we decided 
to conduct Ethidium Bromide displacement assays (Figure 4.17).288 This method was first 
introduced by LePecq and Paoletti289 and is commonly used to evaluate the efficiency of both 
intercalative and non-intercalative drugs.290, 291 Ethidium Bromide assays do not rely on the 
photophysical properties of the naphthalimides, but instead on the inherent fluorescence 
changes observed for ethidium bromide upon displacement from DNA.292 Ethidium Bromide 
is known to be strongly emissive when bound to DNA. The changes in the emission of 
Ethidium Bromide due to the synthesised intercalator displacing Ethidium Bromide in DNA 
can be monitored to obtain the C50 value. 50% reduction of DNA bound Ethidium Bromide 
fluorescence intensity, is described by the C50 value.
47 DMSO was chosen as the solvent for 
these tests, as it was the only solvent in which all synthesised compounds did not precipitate 
out of solution, where it is a standard used solvent for compounds that precipitate in PBS.  
Figure 4.17: Ethidium Bromide Displacement Assay schematic. 
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Figure 4.18: Ethidium Bromide displacement of various concentration of 38, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 38 with 
excitation at 445 nm. 
 
 
Figure 4.19: Ethidium Bromide displacement assays of various concentrations of 38, 39 and 40, in 




The Ethidium Bromide Displacement Assays of 38 (Figure 4.18), 39 and 40 (See Appendix) 
have all displayed a decrease in fluorescence. 38 had displayed the most significant 
fluorescence decrease percentage, compared to compounds 39 and 40 (Figure 4.19). However, 
the relative fluorescence decrease for 38-40 was not significant, which highlights the weak 
DNA binding affinity (See Appendix). 
 
Figure 4.20: Ethidium Bromide displacement of various concentration of 47, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 47 with 
excitation at 445 nm. 
 
Figure 4.21: Ethidium Bromide displacement assays of various concentrations of 47, 48 and 49, in 
DMSO with DNA. 
 107 
The Ethidium Bromide Displacement Assays of 47 (Figure 4.20), 48 and 49 (See Appendix) 
have all displayed a small decrease in fluorescence. 47-49 had all displayed almost identical 
decrease in the relative fluorescence decrease percentage (Figure 4.21). This had also 
highlighted the weak DNA binding affinity of these compounds. 
 
 
Figure 4.22: Ethidium Bromide displacement of various concentration of 97, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 97, with 





Figure 4.23: Ethidium Bromide displacement of various concentration of 98, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 98, with 
excitation at 445 nm. 
 
Figure 4.24: Ethidium Bromide displacement assays of various concentrations of 97 and 98 in 
DMSO with DNA. 
 
 
Absolute concentration of DMSO (moles/L) 
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Model compounds 97 (Figure 4.22) and 98 (Figure 4.23) have also displayed a small decrease 
in fluorescence. Both 97 and 98 had displayed almost identical decrease in the relative 
fluorescence decrease percentage (Figure 4.24), which also demonstrated the weak DNA 
binding affinity of the model compounds. It was therefore decided that a control experiment 
will be undertaken where the same volumes of pure DMSO were added, without any 
naphthalimide compound dissolved. Unfortunately, when the DMSO control experiment was 
conducted, the relative fluorescence decrease was much more significant. This had proven that 
the synthesised compounds 38-40, 47-49, 97 and 98 had very limited DNA binding affinity 
and no firm conclusion could be drawn. It may be concluded that the use of DMSO may have 
affected the results. However, due to being unable to dissolve the compounds tested in PBS, 
the method utilised by Boger et al., had to be used in order to run the EtBr assays in pure 




Figure 4.25: Ethidium Bromide displacement of various concentration of DMSO with DNA, where 










We conducted Ethidium Bromide Assays, but unfortunately the results were inconclusive and 
couldn't conclusively tell us whether these compounds are capable of binding to DNA. In both 
cases, when control experiments were conducted, the results mirrored closely the results seen 
when DNA was added and at this point no firm conclusion can be drawn on whether these 
companies are capable of binding to DNA.   
 
The results from the Ethidium Bromide displacement assays with DNA had indicated a 
decrease in fluorescence emission for compounds 38-40, 47-49, 97 and 98 in DMSO, indicating 
the process of DNA interaction. However, when the exact same study was performed as a 
DMSO dilution equivalent, the decrease in fluorescence was even more significant. This 
corresponds to the compounds having very little affinity for DNA binding, as they are 
undergoing the process of self-assembly. It was therefore concluded that the synthesised 
compounds predominantly undergo the process of self-assembly over DNA binding, as 
indicated by the studies performed.   
 
Examples of other techniques include DNA Melts, Viscometry, Circular Dichroism and 
various other experiments. However, these experiments were not undertaken due to restrictions 
























Chapter 5 Summary and Conclusion 
The work carried out in this research project had the overall goal of synthesising a family of 
squaramide containing bis-naphthalimides and investigating their self-assembly and DNA 
binding properties.   
Chapter 1 gave an introduction to the field of DNA binding molecules and outlined the rationale 
for our compound design. 
 
Chapter 2 detailed the synthesis and attempted synthesis of several families of squaramide bis-
naphthalimide conjugates and outlined the various challenges encountered in synthesis. 
Solubility issues, reduced reactivity, difficulties with isolation and purification hampered 
advances in synthesis and several different approaches were outlined in this chapter. However, 
8 final compounds were successfully isolated and characterised. These compounds included 
the unsubstituted squaramide containing bis-naphthalimides 38-40, 4-nitro containing bis-
naphthalimides 47-49, a bis-naphthalimide without a squaramide moiety 97 and a mono-
naphthalimide 98.  
 
In Chapter 3, the potential self-assembly properties of 38-40, 47-49, 97 and 98 were examined 
and discussed in detail using VT-NMR and a range of spectroscopic techniques. High 
temperature NMR displayed improved resolution of all 1H NMR signals and suggested that a 
significant amount of self-assembly behaviour is likely for these compounds. The UV-Vis 
absorbance and fluorescence emission time studies also displayed dramatic decreases of UV-
Vis absorbance over time, particularly compounds containing a squaramide moiety. Extinction 
coefficient studies were also performed and showed that these compounds all obey the Beer 
Lambert Law, where their absorbance is proportional to their concentration in solution. 
Scanning Electron Microscopy tests have also been undertaken for compounds both in DMSO 
and DMSO:water (50:50) solution. All compounds containing a squaramide moiety had formed 
films in both solutions, while the compounds without a squaramide moiety had formed fibrillar 
networks. These results had strongly indicated the process of self-assembly taking place in the 
squaramide containing bis-naphthalimides.  
 
In Chapter 4, all compounds were examined for their DNA binding ability using a range of 
spectroscopic techniques. These techniques included UV-Vis absorbance and fluorescence 
emission titrations with DNA where initially it was concluded that DNA binding was giving 
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rise to hypochromism in the absorbance spectrum. However, after conducting control 
experiments, it became clear that these changes were inconclusive and may be a result of self-
assembly. Ethidium Bromide assays were also carried out for all synthesised compounds. 
Again, the assays were inconclusive as control experiments were conducted, it was not possible 
to discern with certainty whether DNA binding was occurring. It was evident that self-assembly 
was a predominant feature of these novel compounds and may be preventing DNA binding to 
any meaningful extent. Further techniques are required in this context and may shed light on 
whether or not these molecules are useful as DNA binders.  
 
The future work to continue this project should examine these compounds with previously 
mentioned DNA binding techniques, where the possibility of DNA binding could be more 
easily distinguished from the self-assembly properties. Improving the synthesis and compound 
design to result in a much stronger DNA binding ability could also be explored.  
 
Improving compound design of the desired products could involve the incorporation of urea-
based bis-naphthalimides, where the urea moiety would also bind to DNA phosphate backbone 
through H-bonding due to its strong H-bonding ability. Different linker units in synthesising 
the desired compounds could be substituted, such as ethylene glycol linkers instead of the alkyl 
linkers used, as alkyl linkers are insoluble in water. Ethylene glycols would likely increase the 
water solubility of the target compounds. Changing the DNA binding moiety of the target 
compounds could also aid an improved DNA binding ability. Incorporating pyrene into the 
target structure instead of a naphthalimide moiety would improve the DNA binding ability, as 
it is known to be a strong intercalator. Anthracene could also be used as a substitute for the 
naphthalimide moiety, as it is also a strong intercalator and additionally could be examined 
through other biological tests, as it has  strong antibacterial activity against both Gram-positive 
and Gram-negative bacteria. Additionally, acridine derivatives could also replace 
naphthalimides in the design of the desired compounds, due to the derivatives of acridine 
having both strong DNA intercalating ability, gram positive and also gram negative 
antibacterial ability. For the proposed compound structures, see Figure 5.1. 
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Chapter 6 Experimental  
6.1 General remarks 
1H NMR spectra were recorded using a Bruker Avance III 500 at a frequency of 500.13 MHz, 
and chemical shifts (δ) are reported in parts per million (ppm) with either DMSO-d6 δH 2.50 
ppm) or CDCl3 (δH 7.26 ppm) as an internal reference. The data are reported as chemical shift 
(δ), multiplicity (br = broad, s = singlet, d = doublet, t = triplet, m = multiplet), coupling 
constant (J Hz) and relative integral. 13C NMR spectra were recorded using a Bruker Avance 
III 500 at a frequency of 125.76 MHz and are reported as parts per million (ppm) with either 
DMSO-d6 (δH 39.5 ppm) or CDCl3 (δH 77.2 ppm) as an internal reference. High resolution ESI 
spectra were recorded on an Agilent 6319 LCMS TOF. Analytical TLC was performed using 
pre-coated silica gel plates (Merck Kieselgel 60 F254). Column chromatography was 
performed using high-purity grade silica gel (0.2-0.5 mm). The instrumentation used for IR 
Spectroscopy was NicoletTM iS50 FTIR Spectrometer. Microwave irradiation of reaction 
mixtures was performed using a CEM Discover SP microwave controlled by SynergyTM 
software. Commercial materials were supplied by TCI Europe or Sigma Aldrich and were used 
without further purification. HPLC grade solved were used as received. 
6.2 UV/Vis Measurements  
UV-visible absorption spectra and optical density were recorded by means of a Varian CARY 
50 Spectrophotometer. 5 mg of each compound tested were dissolved in 5 mL of DMSO to 
make each stock solution. Each stock solution was further diluted, where 100 μM stock solution 
for each compound tested in both 12 hour time studies and UV-Extinction Coefficient studies, 
where the path length of the cuvette was 10 mm, as was done with the fluorescence 
measurements The solutions were measured in 3 cm3 (10 mm x 10 mm) cuvettes. The 
wavelength range was 200-900 nm with a scan rate of 600 nm min-1.   
In UV absorbance DNA tests, pH 7.4, 0.01 M PBS solution was made from dissolving 1 tablet 
obtained from Sigma Aldrich in 200 mL deionised H2O, also containing 137 mM NaCl, 2.7 
mM and the PBS solutions used in DNA testing were HPLC grade. Each stock solution was 
made in PBS, where each compound’s concentration was 10 μM. Baseline correction 
measurements were used for all spectra. All solutions were prepared freshly prior to 
measurement. The pH 7.4 of the DNA unbuffered solutions was determined using Jenway 3305 
pH Meter. 
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For DNA testing, deoxyribonucleic acid sodium salt (Sigma Aldrich) (10 mg) was dissolved 
in deionised H2O (20 mL). The solution was divided into 40 Eppendorf tubes (0.5 mL each). 
They were stored at -20 °C to prevent bacterial growth. The concentrations of DNA were 
accurately determined by quantification by UV-Vis analysis. Detection for the presence of 
contaminant proteins in DNA was performed through UV-Vis analysis, where the absorption 
ration A260nm/A280nm must be greater than 1.8 for protein-free DNA. The DNA concentration 
per nucleotide was determined spectrophotometrically using the molar extinction coefficient, 
6600 M-1cm-1 at 260 nm for DNA. Each control experiment was carried out with a stock PBS 
blank equivalent solution to observe any changes in UV absorbance with and without the 
presence of DNA. 
 
6.3  Fluorescence Measurements  
Fluorescence measurements were made with a Varian Cary 50 UV-Vis spectrophotometer 
equipped with a 1.0 cm path length quartz cell. The solvents used were of HPLC grade. The 
concentrations of the compounds under investigation were the same as those used for the UV-
Visible absorption measurements, as detailed in Chapter 3 and Chapter 4. In fluorescence 
emission DNA tests, 0.01 M PBS solution was made from dissolving 1 tablet in 200 mL 
deionised H2O. PBS solution was used in DNA testing were HPLC grade. Each stock solution 
was made in PBS, where each compound’s concentration was 10 μM. Each control experiment 
was carried out with a stock PBS blank equivalent solution to observe any changes in UV 
absorbance with and without the presence of DNA as previously done. 
 
A stock solution of ethidium bromide was prepared by dissolving ethidium bromide (2.5 mg, 
0.63 mmol) in 0.01 M PBS solution (1.0 mL), giving a solution with a concentration of 10 M. 
Assays were carried out by adding 2.1 μL of the stock solution into the cuvette. This was 
followed by the addition of 21 μL of DNA from an Eppendorf made, which was further diluted 
in DMSO to make a 10 μM stock solution for each compound tested. These additions were (4 













3,4-dihydroxycyclobut-3-ene-1,2-dione (2.00 g, 44.0 mmol) was dissolved in EtOH (100 mL) 
followed by a dropwise addition of triethylamine (7.33 mL, 219 mmol). The reaction mixture 
was allowed to reflux at 85 °C for 48 hrs. The product was concentrated in-vacuo to afford the 
crude material. The title compound was purified via column chromatography with 100 % 
DCM to afford a yellow liquid (1.55 g, 39 mmol, 88 %). 1H NMR (500 MHz, DMSO-d6, 298 
K, ppm) δ 6.67 (q, J = 14 Hz, 2H), 3.40 (t, J = 14 Hz, 3H). 13C NMR (126 MHz, DMSO-d6, 










Figure 6.1:  The 1H NMR Spectrum of 50 (500 MHz, DMSO-d6, 298 K.)  
 
 
Figure 6.2:  The 13C NMR Spectrum of 50 (126 MHz, DMSO-d6, 298 K.) 
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tert-Butyl N-(2-aminoethyl)carbamate (51) 
 
 
Ethane-1,2-diamine (28 mL, 25.2 g, 400 mmol) was dissolved in CHCl3 (200 mL) followed by 
a dropwise addition of di-tert-butyl dicarbonate (8.74 g, 40 mmol) in CHCl3 (50 mL) over the 
course of 1 hour. The reaction mixture was allowed to stir at 0° C for 3 hrs. After stirring at 
ambient temperature for 16 hrs, the mixture was washed 3x with water and 2x with brine, dried 
over MgSO4. The product was concentrated in-vacuo to afford a colourless oil (5.80 g, 36 
mmol, 90 %). 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 5.08 (br s, 1H), 3.14 (m, 2H), 
2.88 (t, J = 12 Hz, 2H), 1.70 (s, 1H), 1.40 (m, 3H). 13C NMR (126 MHz, DMSO-d6, 298 K, 
ppm) δ 156.3, 79.3, 79.2, 43.2, 41.8, 40.8, 31.2, 28.4, 28.4, 28.2, with CDCl3 at 77 ppm.  
 
 














Pentane-1,5-diamine (3.51 mL, 3.06 g, 30 mmol) was dissolved in CHCl3 (150 mL) followed 
by a dropwise addition of di-tert-butyl dicarbonate (1.31 g, 6 mmol) in CHCl3 (50 mL) over 
the course of 1 hour. The reaction mixture was allowed to stir at 0° C for 3 hrs. After stirring 
at ambient temperature for 16 hrs, the mixture was washed 3x with water and 2x with brine, 
dried over MgSO4. The product was concentrated in-vacuo to afford a colourless oil (1.03 g, 
5.09 mmol, 85 %). 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 4.544 (br s, 1H), 3.65 (q, J 
= 7 Hz, 2H), 3.12 (q, J = 7 Hz, 2H), 2.78 (s, 2H), 1.52-1.44 (m, 2H, 3H), 1.4 (m, 2H), 1.3 (m, 
2H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 79.1, 64.4, 40.5, 30.9, 29.9, 29.7, 28.4, 





















Octane-1,8-diamine (15.0 g, 104 mmol) was dissolved in CHCl3 (150 mL) followed by a 
dropwise addition of di-tert-butyl dicarbonate (2.95 g, 14.0 mmol) in CHCl3 (50 mL) over the 
course of 1 hour. The reaction mixture was allowed to stir at 0° C for 3 hrs. After stirring at 
ambient temperature for 16 hrs, the mixture was washed 3x with water and 2x with brine, dried 
over MgSO4. The product was concentrated in-vacuo to afford a colourless oil (3.74 g, 15.3 
mmol, 90 %). 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 5.26 (br s, 1H), 2.79 (s, 1H), 
2.39 (m, 2x2H), 1.16 (t, J = 12.5 Hz, 4x2H), 1.13 (d, J = 7 Hz, 3H), 1.04 (q, J = 7.5 Hz, 2x2H). 
13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 155.9, 78.3, 51.3, 42.0, 40.3, 33.6, 30.6, 29.8, 
29.2, 29.1, 28.2, 26.6, 18.0, with CDCl3 at 77 ppm. 
 
 













tert-butyl (2-aminoethyl)carbamate (1.00 g, 6.24 mmol) was dissolved in EtOH (50 mL) 
followed by a dropwise addition of 3,4-diethoxycyclobut-3-ene-1,2-dione (185 µL, 1.25 mmol) 
dissolved in 2 mL of EtOH. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
product was concentrated in-vacuo to afford the crude material. The title compound was 
purified via column chromatography with 94% DCM & 6% MeOH to afford a yellow solid 
(0.44 g, 1.10 mmol, 88 %). M.p. 183-185 °C. 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 
7.43 (br s, 1H), 6.89 (br t, J = 10 Hz, 1H), 3.50 (d, J = 5 Hz, 2H), 3.10 (q, J = 15 Hz, 2H), 1.37 
(s, 3H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 183.0, 156.2, 78.3, 43.6, 41.6, 28.6, 
with DMSO-d6 at 40 ppm. IR (film) νmax (cm
-1): 3341, 2975, 1803, 1691 (C=O stretch), 1646 
(C=O stretch), 1558, 1523, 1448, 1389, 1363, 1271, 1250, 1165, 966, 870, 745, 606, 586, 576, 
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569, 549, 541, 532, 525. HRMS (ESI+): m/z calculated for C18H30N4O6 [M+H]
+ requires 
398.46, found 398.04 (-0.42 ppm).  
 
 

























Figure 6.10:  The 13C NMR Spectrum of 63 (126 MHz, DMSO-d6, 298 K.) 
 
 
Figure 6.11:  LCMS Characterisation of 63: (a) Analytical HPLC trace of purified 63; Rt = 
15.0 mins (0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 
298.1 [M + H]+. (c) Mass Spectrum detected between Rt = 14.6-16 mins (157 scans); Calculated 










tert-butyl (5-aminopentyl)carbamate) (0.64 g, 3.18 mmol) was dissolved in EtOH (50 mL) 
followed by a dropwise addition of 3,4-diethoxycyclobut-3-ene-1,2-dione (97 µL, 0.64 mmol) 
dissolved in 2 mL of EtOH. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
product was concentrated in-vacuo to afford the crude material. The title compound was 
purified via column chromatography with 94% DCM & 6% MeOH to afford a white solid 
(0.25 g, 0.52 mmol, 81 %). 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 7.33 (br s, 1H), 
6.77 (br t, J = 10.5 Hz, 1H), 3.48 (s, 2H), 2.90 (q, J = 13 Hz, 2H), 1.50 (m, 2H), 1.40 (t, J = 15 
Hz, 2H, 3H), 1.27 (q, J = 15.5 Hz, 2H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 182.8, 
168.2, 156.1, 77.8, 43.7, 31.1, 31.0, 29.6, 28.7, 23.6, with DMSO-d6 at 40 ppm. IR (film) 
νmax (cm
-1): 3364, 3172, 2935, 2861, 1799, 1685, 1641, 1564 (C=O stretch), 1518 (C=O 
stretch), 1441, 1456, 1441, 1387, 1364, 1352, 1327, 1310, 1278, 1249, 1169, 1105, 1038, 995, 
948, 872, 820, 757, 607, 541, 531, 507, 504, 496, 493, 489, 487, 481, 476, 473, 465, 457, 454. 
HRMS (ESI+): m/z calculated for C24H42N4O6 [M+H]






Figure 6.12:  The 1H NMR Spectrum of 64 (500 MHz, DMSO-d6, 298 K.) 
 
 








tert-butyl (8-aminooctyl)carbamate) (4.81 g, 19.69 mmol) was dissolved in EtOH (50 mL) 
followed by a dropwise addition of 3,4-diethoxycyclobut-3-ene-1,2-dione (583 µL, 3.94 mmol) 
dissolved in 2 mL of EtOH. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
precipitated product was filtered to afford the crude material. The title compound was a pure 
product and appeared as a yellow solid (1.77 g, 3.12 mmol, 79 %). The deprotection of the N-
Boc groups was carried out in separate reactions, where 10 equivalents of both 
dichloromethane and trifluoroacetic acid have been used in order to progress with the reaction 
pathways. 1H NMR (500 MHz, DMSO-d6, 298 K, ppm) δ 7.40 (br s, 1H), 3.49 (s, 2x2H), 2.88 
(q, J = 13 Hz, 2x2H), 1.50 (d, J = 6.5 Hz, 2H), 1.37 (m, 3x2H, 3H). 13C NMR (126 MHz, 
DMSO-d6, 298 K, ppm) δ 182.8, 43.7, 42.0, 33.7, 33.7, 31.2, 29.5, 29.4, 29.1, 28.7, 26.9, 26.9, 
26.2, with DMSO-d6 at 40 ppm. IR (film) νmax (cm
-1): 3159, 2923, 2848, (1799, 1644, 1563, 
1487 C=O stretch), 1434, 1356, 1311, 1171, 1033, 724, 610, 564, 542, 525, 513, 508, 504, 500. 
HRMS (ESI+): m/z calculated for C30H54N4O6 [M+H]
+ requires 566.78, found 566.26 (-0.52 








Figure 6.14:  The 1H NMR Spectrum of 65 (500 MHz, DMSO-d6, 298 K.) 
 










Naphthalene-1,8-dicarboxylic anhydride (0.28 g, 1.4 mmol) was dissolved in ethanol (20 mL) 
and triethylamine (355 µL, 2.5 mmol) followed by a dropwise addition of 57 (0.20 g, 0.6 mmol) 
in 2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The title 
compound was a precipitate. (0.27 g, 0.48 mmol, 84 %). 1H NMR (500 MHz, DMSO-d6, 358 
K, ppm) δ 8.26 (d, J = 7 Hz, 1H), 8.19 (d, J = 8 Hz, 1H), 7.65 (t, J = 15.5 Hz, 1H), 7.43 (br s, 
1H), 4.15 (t, J = 11 Hz, 2H), 3.67 (d, J = 4 Hz, 2H). 13C NMR (126 MHz, DMSO-d6, 298 K, 
ppm) δ 183.4, 168.7, 164.1, 134.7, 131.5, 131.0, 127.7, 127.5, 122.4, 56.5, 49.1, 19.0, with 
DMSO-d6 at 40 ppm. IR (film) νmax (cm
-1): 3302, 1795 (C=O stretch), 1691 (C=O stretch), 
1651, 1625, 1583, 1537, 1463, 1441, 1416, 1385, 1339, 1315, 1280, 1233, 1168, 1143, 1120, 
1102, 1043, 877, 855, 844, 788, 774, 739, 669, 617, 567, 542, 522. HRMS (ESI+): m/z 
calculated for C38H34N4O6 [M+H]









Figure 6.16:  The 1H NMR Spectrum of 38 (500 MHz, DMSO-d6, 298 K.)  
 
 
Figure 6.17:  The 1H NMR Spectrum of 38 at 358 K (500 MHz, DMSO-d6, 358 K.)  
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Figure 6.18:  The 13C NMR Spectrum of 38 (126 MHz, DMSO-d6, 298 K.)  
 
Figure 6.19: LCMS Characterisation of 38: (a) Analytical HPLC trace of precipitate 38; Rt 
= 25.0 mins (0-100% MeCN over 26 mins, λ = 254 nm). (b) Extracted Ion Chromatogram for 
558.58 [M + H]+. (c) Mass Spectrum detected between Rt = 24.0-26.0 mins (354 scans); 










Naphthalene-1,8-dicarboxylic anhydride (0.22 g, 1.1 mmol) was dissolved in ethanol (20 mL) 
and triethylamine (280 µL, 2.0 mmol) followed by a dropwise addition of dissolved 5,5'-((3,4-
dioxocyclobut-1-ene-1,2-diyl)bis(azanediyl))bis(pentan-1-aminium) (0.24 g, 0.5 mmol) in 2 
mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The title 
compound was a precipitate. (0.140 g, 0.22 mmol, 89 %). 1H NMR (500 MHz, DMSO-d6, 358 
K, ppm) δ 8.47 (d, J = 7 Hz, 1H), 8.37 (d, J = 8 Hz, 1H), 7.82 (t, J = 15.5 Hz, 1H), 7.09 (br s, 
1H), 4.08 (d, J = 6 Hz, 2H), 3.51 (d, J = 6 Hz, 2H), 1.71 (d, J = 6 Hz, 2H), 1.62 (d, J = 6.5 Hz, 
2H), 1.43 (t, J = 14 Hz, 2H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 182.8, 168.2, 
163.8, 134.7, 131.7, 131.1, 127.8, 127.7, 122.5, 43.6, 31.2, 31.0, 27.7, 23.9, with DMSO-d6 at 
40 ppm. IR (film) νmax (cm
-1): 3249, 2931, 2854, 1794 (C=O stretch), 1695 (C=O stretch), 
1656, 1625, 1547, 1463, 1427, 1387, 1339, 1275, 1245, 1173, 1095, 1068, 1045, 996, 960, 911, 
848, 815, 800, 778, 738, 686, 652, 608, 591, 573, 544, 534, 528. HRMS (ESI+): m/z calculated 
for C38H34N4O6 [M+H]






Figure 6.20:  The 1H NMR Spectrum of 39 (500 MHz, DMSO-d6, 298 K.)   
 
 




Figure 6.22:  The 13C NMR Spectrum of 39 (126 MHz, DMSO-d6, 298 K.) 
  





Figure 6.24:  LCMS Characterisation of 39: (a) Analytical HPLC trace of precipitate 39; 
Rt = 29.0 mins (0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram 
for 642.7 [M + H]+. (c) Mass Spectrum detected between Rt = 28.0-29.5 mins (354 scans); 






Naphthalene-1,8-dicarboxylic anhydride (0.181 g, 0.41 mmol) was dissolved in ethanol (20 
mL) and triethylamine (232 µL, 1.66 mmol) followed by a dropwise addition of dissolved 8,8'-
((3,4-dioxocyclobut-1-ene-1,2-diyl)bis(azanediyl))bis(octan-1-aminium) (0.2 g, 0.41 mmol) in 
2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The title 
compound was a precipitate. (0.135 g, 0.19 mmol, 77 %). 1H NMR (500 MHz, DMSO-d6, 358 
K, ppm) δ 8.54 (d, J = 6 Hz, 1H), 8.45 (d, J = 8 Hz, 1H), 7.89 (t, J = 14 Hz, 1H), 7.13 (br s, 
1H), 4.123 (m, 2H), 3.54 (m, 3x2H), 1.58 (m, 2H), 1.36 (m, 3x2H). 13C NMR (126 MHz, 
DMSO-d6, 298 K, ppm) δ 190.9, 163.9, 134.8, 131.8, 131.2, 128.0, 127.7, 122.5, 56.5, 43.7, 






2925, 2852, 1799 (C=O stretch), 1698 (C=O stretch), 1641, 1575, 1432, 1388, 1355, 1236, 
1201, 1173, 1132, 1078, 1030, 846, 779, 720, 603, 546, 535, 521, 516, 509, 505. HRMS (ESI+): 
m/z calculated for C44H46N4O6 [M+H]
+ requires 726.87, found 726.34 (-0.53 ppm).  
 
 
Figure 6.25:  The 1H NMR Spectrum of 40 (500 MHz, DMSO-d6, 298 K.) 
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Figure 6.26:  The 1H NMR Spectrum of 40 at 358 K (500 MHz, DMSO-d6, 358 K.)  
 
 





4-Nitronaphthalene-1,8-dicarboxylic anhydride (0.27 g, 1.1 mmol) was dissolved in ethanol 
(20 mL) and triethylamine (280 µL, 2.0 mmol) followed by a dropwise addition of dissolved 
2,2’-((3,4-dioxocyclobut-1-ene-1,2-diyl)bis(azanediyl))bis(ethan-1-aminium) (0.20 g, 0.5 
mmol) in 2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
title compound was a precipitate. (0.172 g, 0.26 mmol, 86 %). 1H NMR (500 MHz, DMSO-
d6, 358 K, ppm) δ 8.59 (m, 1H), 8.01 (t, J = 15.5 Hz, 1H), 7.53 (br s, 1H), 4.25 (m, 2H), 3.77 
(m, 2H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 183.4, 168.7, 164.1, 134.7, 131.5, 
131.0, 127.7, 127.5, 122.4, 56.5, 49.1, 19.0, with DMSO-d6 at 40 ppm. IR (film) νmax (cm
-1): 
3302, 1795 (C=O stretch), 1691 (C=O stretch), 1651, 1625, 1583, 1537, 1463, 1441, 1416, 
1385, 1339, 1315, 1280, 1233, 1168, 1143, 1120, 1102, 1043, 877, 855, 844, 788, 774, 739, 
669, 617, 567, 542, 522. HRMS (ESI+): m/z calculated for C38H34N4O6 [M+H]
+ requires 
642.2509, found 642.2367 (-0.48 ppm).  
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Figure 6.28:  The 1H NMR Spectrum of 47 (500 MHz, DMSO-d6, 298 K.)  
 
 




Figure 6.30:  The 13C NMR Spectrum of 47 (126 MHz, DMSO-d6, 298 K.)  
 
  




Figure 6.32:  HRMS spectrum of 47. 






























































Figure: Zoomed Compound spectra view 
(red boxes indicating expected theoretical isotope spacing and abundance)








Figure: Extracted ion chromatogram (EIC) of compound.
Figure: Full range view of Compound spectra and potential adducts.






4-Nitronaphthalene-1,8-dicarboxylic anhydride (0.22 g, 0.91 mmol) was dissolved in ethanol 
(20 mL) and triethylamine (232 µL, 1.65 mmol) followed by a dropwise addition of dissolved 
5,5'-(3,4-dioxocyclobut-1-ene-1,2-diyl)bis(azanediyl))bis(pentan-1-aminium) (0.2 g, 0.41 
mmol) in 2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
title compound was a precipitate. (0.162 g, 0.22 mmol, 88 %). 1H NMR (500 MHz, DMSO-
d6, 358 K, ppm) δ 8.60 (m, 1H), 8.07 (t, J = 16 Hz, 1H), 7.19 (br s, 1H), 4.10 (m, 2H), 3.499 
(q, J = 14 Hz, 2H), 1.76 (m, 2H), 1.61 (t, J = 14 Hz, 2H), 1.46 (m, 2H). 13C NMR (126 MHz, 
DMSO-d6, 298 K, ppm) δ 181.0, 163.5, 162.7, 149.6, 132.0, 130.5, 130.0, 130.0, 129.2, 128.8, 
127.1, 124.7, 123.2, 123.2, 55.4, 43.6, 27.5, 24.5, 24.4, 23.9, with DMSO-d6 at 40 ppm. IR 
(film) νmax (cm
-1): (2936, 1801 (C=O stretch), 1702 (C=O stretch), 1656, 1623, 1583, 1524, 
1436, 1409, 1339, 1229, 1183, 1064, 871, 835, 786, 760, 732, 711, 582, 568, 544, 538, 526. 
HRMS (ESI+): m/z calculated for C38H34N4O6 [M+H]





Figure 6.34:  The 1H NMR Spectrum of 48 (500 MHz, DMSO-d6, 298 K.)  
 
 




Figure 6.36:  The 13C NMR Spectrum of 48 (126 MHz, DMSO-d6, 298 K.)  
 
 
Figure 6.37:  HRMS spectrum of 48. 
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4-Nitronaphthalene-1,8-dicarboxylic anhydride (0.189 g, 0.77 mmol) was dissolved in ethanol 
(20 mL) and triethylamine (197 µL, 1.41 mmol) followed by a dropwise addition of dissolved 
8,8'-((3,4-dioxocyclobut-1-ene-1,2-diyl)bis(azanediyl))bis(octan-1-aminium) (0.2 g, 0.35 
mmol) in 2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 12 hrs. The 
title compound was a precipitate. (0.158 g, 0.19 mmol, 79 %). 1H NMR (500 MHz, DMSO-
d6, 358 K, ppm) δ 8.59 (m, 1H), 8.07 (m, 1H), 7.18 (br s, 1H), 4.052 (q, J = 20.5 Hz, 2H), 1.67 
(t, J = 11 Hz, 2H), 1.53 (t, J = 11 Hz, 2H), 1.344 (m, 5x2H). 13C NMR (126 MHz, DMSO-d6, 
298 K, ppm) δ 188.2, 168.4, 163.3, 149.5, 133.7, 132.1, 131.6, 130.8, 130.5, 130.3, 130.0, 
129.1, 124.8, 124.7, 123.1, 43.7, 34.4, 31.2, 29.1, 28.9, 27.7, 26.9, 26.2, with DMSO-d6 at 40 
ppm. IR (film) νmax (cm
-1): (3168, 2926, 2851, 1797 (C=O stretch), 1704 (C=O stretch), 1663, 
1568, 1527, 1435, 1347, 1231, 1087, 1035, 1027, 835, 785, 761, 728, 615, 574, 563, 549, 539, 
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511. HRMS (ESI+): m/z calculated for C44H44N6O10 [M+H]
+ requires 816.87, found 816.31 (-
0.56 ppm).  
 
 





Figure 6.40:  The 1H NMR Spectrum of 49 at 358 K (500 MHz, DMSO-d6, 358 K.)  
 





Figure 6.42:  HRMS spectrum of 49. 
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Naphthalene-1,8-dicarboxylic anhydride (0.60 g, 3.0 mmol) was dissolved in ethanol (20 mL) 
and triethylamine (775 µL, 5.5 mmol) followed by a dropwise addition of dissolved 1,8-
octanediamine (0.20 g, 1.4 mmol) in 2 mL of ethanol. The reaction mixture was allowed to 
reflux at 85 °C for 12 hrs. The title compound was concentrated in-vacuo, which afforded a 
precipitate. The product was purified from column chromatography with 90% DCM, 10% 
MeOH. (0.17 g, 0.37 mmol, 84 %). 1H NMR (500 MHz, DMSO-d6, 358 K, ppm) δ 8.50 (s, 
1H), 8.42 (s, 1H), 4.07 (s, 2x2H), 1.67 (s, 2x2H),  1.36 (s, 4x2H). 13C NMR (126 MHz, DMSO-
d6, 298 K, ppm) δ 163.6, 162.7, 162.0, 138.1, 136.5, 134.8, 132.9, 132.0, 130.4, 129.1, 125.1, 
122.5, 120.7, 55.3, 45.2, 43.9, 36.3, 31.2, 30.5, 19.1, 14.0, with DMSO-d6 at 40 ppm. IR (film) 
νmax (cm
-1): 2929, 2865, 1688 (C=O stretch), 1651, 1624, 1586, 1514, 1474, 1458, 1437, 1414, 
1386, 1340, 1320, 1266, 1240, 1230, 1197, 1184, 1163, 1138, 1101, 1075, 1033, 1007, 952, 
899, 877, 845, 800, 774, 732, 689, 630, 606, 594, 583, 570, 558, 546, m544, 536, 534, 521, 
495. HRMS (ESI+): m/z calculated for C32H28N2O4 [M+H]
+ requires 505.59, found 505.07 (-
0.52 ppm).  
Figure 6.44:  The 1H NMR Spectrum of 97 (500 MHz, DMSO-d6, 298 K.) 
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Figure 6.45:  The 1H NMR Spectrum of 97 at 358 K (500 MHz, DMSO-d6, 358 K.)  
 
 













Naphthalene-1,8-dicarboxylic anhydride (0.60 g, 3.0 mmol) was dissolved in ethanol (20 mL) 
and triethylamine (775 µL, 5.5 mmol) followed by a dropwise addition of 1-aminobutane 
(0.20 g, 1.4 mmol) in 2 mL of ethanol. The reaction mixture was allowed to reflux at 85 °C for 
12 hrs. The product was purified from column chromatography with 95% DCM, 5% MeOH. 
The title compound was a precipitate (0.17 g, 0.37 mmol, 83 %). 1H NMR (500 MHz, DMSO-
d6, 298 K, ppm) δ 8.41 (m, 1H), 7.82 (q, J = 15.5 Hz, 1H), 4.00 (t, J = 15 Hz, 2H), 1.58 (m, 
2H), 1.33 (m, 2H), 0.91 (t, J = 15 Hz, 3H). 13C NMR (126 MHz, DMSO-d6, 298 K, ppm) δ 
163.8, 134.7, 131.7, 131.1, 127.7, 127.6, 122.4, 55.4, 30.1, 20.3, 14.2, with DMSO-d6 at 40 
ppm. IR (film) νmax (cm
-1): 3706, 3680, 3665, 2972, 2949, 2922, 2866, 2844, 2826, 2076, 2053, 
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1696 (C=O stretch), 1654, 1623, 1590, 1511, 1466, 1454, 1437, 1414, 1386, 1346, 1260, 1234, 
1204, 1194, 1136, 1115, 1063, 1057, 1051, 1032, 1016, 936, 869, 846, 797, 779, 737, 686, 651, 
565, 556, 550, 546, 539, 530, 523, 500. HRMS (ESI+): m/z calculated for 
C16H15NO2 [M+H]
+ requires 254.11, found 253.67 (-0.44 ppm).  
 
 
Figure 6.48:  The 1H NMR Spectrum of 98 (500 MHz, DMSO-d6, 298 K.)  
 154 
 
Figure 6.49:  The 13C NMR Spectrum of 98 (126 MHz, DMSO-d6, 298 K.)  
 
 




Figure 6.51:  LCMS Characterisation of 98: (a) Analytical HPLC trace of precipitate 98; 
Rt = 43.0 mins (0-100% MeCN over 30 mins, λ = 254 nm). (b) Extracted Ion Chromatogram 
for 254.3 [M + H]+. (c) Mass Spectrum detected between Rt = 43.0-45.0 mins (354 scans); 
Calculated for [M + H]+ = 254.3; Mass Found (ESI+) = 254.0 [M + H]+. Also found 295.0 [M 
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Figure A1.1:  1H NMR (500 MHz, DMSO-d6) of 40 at 298 K. 
 











Figure 2.1: UV-VIS absorbance time study of 39 over the course of 12 hours in DMSO 










Figure A2.2: UV-VIS absorbance time study of 40 over the course of 12 hours in DMSO, 




Figure A2.3:  UV-VIS absorbance time study of 47 over the course of 12 hours in DMSO,  









Figure A2.4:  UV-VIS absorbance time study of 48 over the course of 12 hours in DMSO 






Figure A2.5:  UV-VIS absorbance time study of 49 over the course of 12 hours in DMSO, 








Figure A2.6:  UV-VIS absorbance time study of 97 over the course of 12 hours in DMSO, 
and its absorbance at 345nm vs the concentration (mg/mL) of 97. 
 
 
Figure A2.7:  Fluorescence intensity (au) time study of 39, with an excitation wavelength at 






Figure A2.8:  Fluorescence intensity (au) time study of 40, with an excitation wavelength at 
440 nm over the course of 12 hours in DMSO. 
 
Figure A2.9: Fluorescence intensity (au) time study of 97, with an excitation wavelength at 





Figure A2.10: Fluorescence intensity (au) time study of 98, with an excitation wavelength at 
450 nm over the course of 12 hours in DMSO. 
 







Figure A2.12: Fluorescence intensity (au) time study of 38, with an excitation wavelength at 




Figure A2.13: Fluorescence intensity (au) time study of 40 with an excitation wavelength at 





Figure A2.14: Fluorescence intensity (au) time study of 97, with an excitation wavelength at 
440 nm over the course of 12 hours in DMSO. 
 
 
Figure A2.15: Fluorescence intensity (au)  time study of 98, with an excitation wavelength at 
440 nm over the course of 12 hours in DMSO. 
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Figure A2.16:UV-Vis Absorbance of 2.6mg of 39 and its absorbance at 345nm vs the    
concentration (M) of 39. 
 
 
Figure A2.17: UV-Vis Absorbance of 5.2mg of 39 and its absorbance at 345nm vs the 
concentration (M) of 39. 
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Figure A2.18: UV-Vis Absorbance of 2.6mg of 40 and its absorbance at 345nm vs the 
concentration (M) of 40. 
 
Figure A2.19: UV-Vis Absorbance of 5.2mg of 40 and its absorbance at 345nm vs the 





Figure A2.20: UV-Vis Absorbance of 2.6mg of 47 and its absorbance at 345nm vs the 
concentration (M) of 47. 
 
 
Figure A2.21: UV-Vis Absorbance of 5.2mg of 47 and its absorbance at 345nm vs the 
concentration (M) of 47. 
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Figure A2.22: UV-Vis Absorbance of 2.6mg of 48 and its absorbance at 345nm vs the 
concentration (M) of 48. 
 
 
Figure A2.23: UV-Vis Absorbance of 5.2mg of 48 and its absorbance at 345nm vs the 
concentration (M) of 48. 
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Figure A2.24: UV-Vis Absorbance of 2.6mg of 49 and its absorbance at 345nm vs the 
concentration (M) of 49. 
 
 
Figure A2.25: UV-Vis Absorbance of 5.2mg of 49 and its absorbance at 345nm vs the 
concentration (M) of 49. 
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Figure A2.26: UV-Vis Absorbance of 2.6mg of 97 and its absorbance at 345nm vs the 
concentration (M) of 97. 
 
Figure A2.27: UV-Vis Absorbance of 5.2mg of 97 and its absorbance at 345nm vs the 





Figure A2.28: UV-Vis Absorbance of 2.6mg of 98 and its absorbance at 345nm vs the 
concentration (M) of 98. 
 
Figure A2.29: UV-Vis Absorbance of 5.2mg of 98 and its absorbance at 345nm vs the 





Figure A2.30: Scanning electron microscopy (SEM) images of compound 40 spotted with Au, 
(A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000; (E): Mag x 8000.  
 
Figure A2.31: Scanning electron microscopy (SEM) images of compound 98 spotted with Au 





Figure A2.32: Scanning electron microscopy (SEM) images of compound 40 spotted with Au 
in DMSO:H2O 50:50, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000;                  
(E): Mag x 6000. 
 
Figure A2.33: Scanning electron microscopy (SEM) images of compound 39 in DMSO:H2O 




Figure A2.34: Scanning electron microscopy (SEM) images of compound 39 in DMSO:H2O 






Figure A2.35: Scanning electron microscopy (SEM) images of compound 40 in DMSO:H2O 





Figure A2.36: Scanning electron microscopy (SEM) images of compound 98 spotted with Au 
in DMSO:H2O 50:50, (A): Mag x 100; (B): Mag x 200; (C): Mag x 1000; (D): Mag x 4000;                  






Figure A2.37: Scanning electron microscopy (SEM) images of compound 39 in DMSO:H2O 




Figure A2.38: Scanning electron microscopy (SEM) images of compound 39 in DMSO:H2O 




Figure A2.39: Scanning electron microscopy (SEM) images of compound 40 in DMSO:H2O 






Figure A3.1: UV-VIS absorbance of 39, with DNA concentration increases of (0.00005 
mg/mL) for a total of 25 runs with DNA. 
 
 
Figure A3.2: UV-VIS absorbance of 40, with DNA concentration increases of (0.00005 





Figure A3.3: UV-VIS absorbance of 48, with DNA concentration increases of (0.00005 
mg/mL) for a total of 25 runs with DNA. 
 
 
Figure A3.4: UV-VIS absorbance of 49, with DNA concentration increases of (0.00005 




Figure A3.5: UV-VIS absorbance of 39, with PBS equivalents of DNA concentration 
increases of (0.00005 mL) for a total of 25 runs with PBS. 
 
Figure A3.6: UV-VIS absorbance of 40, with PBS equivalents of DNA concentration 
increases of (0.00005 mL) for a total of 25 runs with PBS. 
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Figure A3.7: UV-VIS absorbance of 39, with PBS equivalents of DNA concentration 
increases of (0.00005 mL) for a total of 25 runs with PBS. 
 
 
Figure A3.8: UV-VIS absorbance of 40, with PBS equivalents of DNA concentration 
increases of (0.00005 mL) for a total of 25 runs with PBS.  
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Figure A3.9: UV-VIS absorbance of 48, with PBS equivalents of DNA concentration 




Figure A3.10: UV-VIS absorbance of 49, with PBS equivalents of DNA concentration 




Figure A3.11: Fluorescence intensity of 39, with an excitation wavelength at 400 nm, with an 




Figure A3.12: Fluorescence intensity of 40, with an excitation wavelength at 400 nm, with an 






Figure A3.13: Ethidium Bromide displacement of various concentration of 39, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 39. 
 
Figure A3.14: Ethidium Bromide displacement of various concentration of 40, in DMSO with DNA, 





Figure A3.15: Ethidium Bromide displacement of various concentration of 48, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 48. 
 
 
Figure A3.16: Ethidium Bromide displacement of various concentration of 49, in DMSO with DNA, 
where the blue trace indicates the EtBr and DMSO solution without DNA and 49. 
 
 
 
 
